L-cysteine ethyl ester prevents and reverses acquired physical dependence on morphine in male Sprague Dawley rats

Abstract

The molecular mechanisms underlying the acquisition of addiction/dependence on morphine may result from the ability of the opioid to diminish the transport of L-cysteine into neurons via inhibition of excitatory amino acid transporter 3 (EAA3). The objective of this study was to determine whether the co-administration of the cell-penetrant L-thiol ester, L-cysteine ethyl ester (L-CYSee), would reduce physical dependence on morphine in male Sprague Dawley rats. Injection of the opioid-receptor antagonist, naloxone HCl (NLX; 1.5 mg/kg, IP), elicited pronounced withdrawal phenomena in rats which received a subcutaneous depot of morphine (150 mg/kg) for 36 h and were receiving a continuous infusion of saline (20 μL/h, IV) via osmotic minipumps for the same 36 h period. The withdrawal phenomena included wet-dog shakes, jumping, rearing, fore-paw licking, 360° circling, writhing, apneas, cardiovascular (pressor and tachycardia) responses, hypothermia, and body weight loss. NLX elicited substantially reduced withdrawal syndrome in rats that received an infusion of L-CYSee (20.8 μmol/kg/h, IV) for 36 h. NLX precipitated a marked withdrawal syndrome in rats that had received subcutaneous depots of morphine (150 mg/kg) for 48 h) and a co-infusion of vehicle. However, the NLX-precipitated withdrawal signs were markedly reduced in morphine (150 mg/kg for 48 h)-treated rats that began receiving an infusion of L-CYSee (20.8 μmol/kg/h, IV) at 36 h. In similar studies to those described previously, neither L-cysteine nor L-serine ethyl ester (both at 20.8 μmol/kg/h, IV) mimicked the effects of L-CYSee. This study demonstrates that 1) L-CYSee attenuates the development of physical dependence on morphine in male rats and 2) prior administration of L-CYSee reverses morphine dependence, most likely by intracellular actions within the brain. The lack of the effect of L-serine ethyl ester (oxygen atom instead of sulfur atom) strongly implicates thiol biochemistry in the efficacy of L-CYSee. Accordingly, L-CYSee and analogs may be a novel class of therapeutics that ameliorate the development of physical dependence on opioids in humans.

Introduction

There are numerous problems faced by clinicians treating patients with opioid use disorder (OUD) and other substance use disorders (SUDs) (McCarberg, 2011; Heberlein et al., 2012; Garcia-Portilla et al., 2014; Hah et al., 2017; Dydyk et al., 2022; 2023; Matson et al., 2022; Horn et al., 2023). With regard to managing pain in the general population, the key issues are how to provide μ-opioid receptor (μ-OR) agonist (e.g., fentanyl)-induced analgesia without eliciting 1) euphoria, 2) physical dependence and/or psychological addiction, 3) hyperalgesia, and 4) any combination of the aforementioned conditions (Benyamin et al., 2008; Volkow et al., 2018; Mercadante et al., 2019; Manhapra, 2022; Preux et al., 2022; Balanaser et al., 2023). With respect to treating moderate-to-severe OUD (DSM-5 terminology for opioid addiction in 10%–20% of people who have liability for SUD), the key issues are 1) how to manage the often severe opioid withdrawal (all current strategies to manage opioid withdrawal are inadequate); 2) how to manage patients who have gone through withdrawal and need medication to block euphoria and/or physical dependence, with the three medications available, naltrexone, buprenorphine, and methadone, all having strengths, but major weaknesses; and 3) how to avoid opioid euphoria and/or physical dependence in patients with moderate-to-severe OUD who currently are sober, but require μ-OR agonist analgesia (Humphreys et al., 2022; Jiménez-Fernández et al., 2022; Torres-Lockhart et al., 2022; Alvarez-Perez et al., 2023; Biancuzzi et al., 2023; Frankeberger et al., 2023). With respect to effectively treating SUD involving opioids and other substances (e.g., alcohol, cannabinoids, benzodiazepines, and psycho-stimulants), in 10%–20% of the population prone to SUD, the important issue is how to provide (yet to be developed) effective therapeutics that will attenuate/block dopamine surge-mediated euphoria of each of these families of brain-reward drugs as an adjunct to treating addictive diseases (Chartoff and Connery, 2014; Stephan and Parsa, 2016; Horsfall and Sprague, 2017; Bechara et al., 2019; Serafini and Zachariou, 2019). With respect to making opioid analgesics safer, we lack drugs that effectively modulate the actions of opioids to improve their analgesic profile. The therapeutics should 1) not interfere with or promote opioid analgesia, 2) prevent the acquisition of physical dependence and psychological addiction to opioids, 3) block opioid-induced respiratory depression (OIRD), or 4) stop the development of hyperalgesia (Benyamin et al., 2008; Morgan and Christie, 2011; Volkow et al., 2018; Mercadante et al., 2019; Manhapra, 2022; Preux et al., 2022; Balanaser et al., 2023).

Trivedi et al. (2014) reported that morphine-induced dependence/addiction may involve redox-based changes in global DNA methylation and retrotransposon transcription via the blockade of excitatory amino acid transporter type 3 (EAA3; also known as EAAC1)-dependent uptake of the amino acid, L-cysteine, into brain neurons. Some of the temporal steps described by Trivedi et al. (2014) (see Figure 5 of Trivedi et al., 2014) and others (Lin et al., 2001; Ikemoto et al., 2002; Mao et al., 2002; Xu et al., 2003; Xu et al., 2006; Christie, 2008; Yang et al., 2008; Wang et al., 2009; Daijo et al., 2011; Gutowicz et al., 2011; Liu et al., 2011; Maze and Nestler, 2011; Lim et al., 2012; Sun et al., 2012; Browne et al., 2020) are as follows: 1) morphine blockade of L-cysteine uptake into neurons by G protein-dependent inhibition of EAA3 activity, 2) resulting decreases in intracellular levels of L-cysteine, L-glutathione, and the methylation index, namely, S-adenosyl-methionine/S-adenosyl-homocysteine (SAM/SAH ratio), 3) decreases in the methylation status of global CpG (regions of DNA where a cytosine nucleotide is followed by a guanine nucleotide in the linear sequence of bases along its 5′ → 3′ direction) and in CpG methylation of long interspersed nuclear element-1 (LINE-1) retrotransposon regulatory regions, and 4) activation of transcription of previously silenced LINE-1 genes. Thus, we hypothesized that co-administration of cell-permeant versions of L-cysteine, such as L-cysteine ethyl ester (L-CYSee) (Goto et al., 1983; Hisadome et al., 1986a; Hisadome et al., 1986b; Hisadome et al., 1988; Servin et al., 1988; Hisadome et al., 1990; Schöneich et al., 1992; Hobbs et al., 1993; Fukui et al., 1994; Ding and Demple, 1998; Galanakis et al., 2004; Mosier-Boss and Lieberman, 2005; Perissinotti et al., 2005; Defonsi Lestard et al., 2013; Mendoza et al., 2013; Arias et al., 2019), may prevent the acquisition of physical dependence on morphine and reverse established dependence on the opioid. Previously, we reported that L-CYSee (Lewis et al., 2022), L-cysteine methyl ester (Getsy et al., 2022a), and other thiolesters and related compounds (Baby et al., 2021; Baby et al., 2021; Gaston et al., 2021; Jenkins et al., 2021; Getsy et al., 2022b; Getsy et al., 2022c; Getsy et al., 2022d; Getsy et al., 2022e; Getsy et al., 2022f) prevent and/or reverse the adverse effects of morphine and fentanyl on ventilatory parameters, arterial blood–gas chemistry (pH, pCO₂, pO₂, and sO₂), and alveolar–arterial gradient (index of alveolar gas exchange in the lungs) in freely-moving rats without compromising opioid-induced analgesia or sedation. We now provide evidence that administration of L-CYSee prevents the acquisition of physical dependence, as measured by markedly fewer withdrawal phenomena in response to administration of the opioid receptor antagonist, naloxone HCl (NLX), in freely-moving male rats, and reverses established dependence. The lack of effect of L-cysteine and L-serine ethyl ester (L-SERee, oxygen atom instead of a sulfur atom as in L-CYSee) in these paradigms suggests that the efficacy of L-CYSee involves its cell penetrability in brain regions vital to the expression of morphine dependence, and points to the vital role of thiol biochemistry in the biological efficacy of L-CYSee.

Materials and methods

Permissions, rats, and surgical procedures

All studies were carried out in strict accordance with the NIH Guide for Care and Use of Laboratory Animals (NIH Publication No. 80-23) revised in 1996 and in strict compliance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (http://www.nc3rs.org.uk/). All protocols involving the use of rats were approved by the Animal Care and Use Committees of Galleon Pharmaceuticals (PC0022), Case Western Reserve University (2015-0025), and the University of Virginia (3642-09-07). Adult male Sprague Dawley rats of approximately 12 weeks of age at the time of study were purchased from Harlan Industries (Madison, WI, United States). The rats were given 5 days to recover from transportation before being subjected to surgeries, as described in this paragraph. (+)-Morphine sulfate was obtained from Baxter Healthcare (Deerfield, IL, United States). L-cysteine hydrochloride monohydrate (L-cysteine HCl) powder (C7880, PubChem Substance ID:24892992), L-cysteine ethyl ester hydrochloride (L-CYSee HCl) powder (C121908, PubChem Substance ID: 24892386), and L-serine ethyl ester hydrochloride (L-SERee HCl) powder (223123; PubChem Substance ID:24853367) were divided into 100 mg amounts under N₂ gas and stored at 4°C. Solutions of L-cysteine HCl, L-CYSee HCl, and L-SERee HCl were dissolved in saline and brought to pH 7.2 with 0.1 M NaOH at room temperature immediately before use. Naloxone hydrochloride dihydrate powder (BP548; PubChem Substance ID: 24278050) was obtained from Sigma-Aldrich (St. Louis, MO, USA) and was dissolved in saline at pH 7.2 with 0.1 M NaOH at room temperature immediately before use. On the day of the study, all arterial and venous catheters were flushed with 0.3 mL of phosphate-buffered saline (0.1 M, pH 7.4) 3–4 h before commencement of the study. All studies were done in a quiet room with a relative humidity of 50% ± 2% and room temperature of 21.3°C ± 0.2°C. Every group described in this study contained nine rats. Other than the described surgeries (see the next section), no rat had a prior history of use in any experimental protocol and was used in only one protocol in the present study. The times at which the surgeries were performed will be described herein. Surgery times from the initiation of anesthesia to final closing of all wounds took approximately a) 20 min for the placement of one venous catheter, b) 25 min for the placement of two venous catheters, c) 30 min for the placement of two intravenous and one arterial catheter, and d) 20 min for intravenous catheterization in which the connected osmotic minipump is placed subcutaneously. Two protocols were as follows: 1) Examine the ability of L-CYSee and L-cysteine (behavioral and cardiorespiratory studies), and L-SERee (behavioral study only) to prevent the acquisition of physical dependence on morphine upon 36 h exposure to the opioid and test compounds. The question addressed whether treatment with L-CYSee, for example, diminishes NLX-precipitated withdrawal phenomena; and 2) examine whether the introduction of L-CYSee or L-cysteine (behavioral and cardiorespiratory studies) or L-SERee (behavioral study only) at 36 h of morphine treatment reverses established physical dependence on morphine, as tested after 48 h of morphine treatment. The question addressed for the second protocol is whether co-treatment for 12 h with L-CYSee, for example, reverses existing physical dependence on morphine, as expressed by markedly diminished NLX-precipitated withdrawal phenomena.

Protocols to determine the effects of L-CYSee on physical dependency of morphine and prevention of morphine dependence—36-h studies

Reversal of morphine dependence—48-h studies

Data analyses

The directly recorded and arithmetically derived parameters were statistically analyzed. All data are presented as mean ± SEM and were evaluated using one-way ANOVA, followed by Bonferroni corrections for multiple comparisons between means using the error mean square terms from each ANOVA analysis (Wallenstein et al., 1980; Ludbrook, 1998; McHugh, 2011), as detailed previously (Getsy et al., 2023a; Getsy et al., 2023b). A p < 0.05 value denoted the initial level of statistical significance that was modified according to the number of comparisons between means, as described by Wallenstein et al. (1980). The modified t-statistic is t = (mean group 1—mean group 2)/[s x (1/n₁ + 1/n₂)^1/2], where s² = the mean square within groups obtained from ANOVA (the square root of this value is used in the modified t-statistic formula), and n₁ and n₂ are the number of rats in each group under comparison. Based on Bonferroni’s inequality, a conservative critical value for modified t-statistics can be obtained from the tables of t-distribution using a significance level of P/m, where m is the number of comparisons to be made between groups (Winer, 1971). The degrees of freedom are those of the mean square for within group variation from the ANOVA table. The critical Bonferroni value can be approximated from the tables of the normal curve by t* = z + (z + z³)/4n, with n being the degrees of freedom and z being the critical normal curve value for P/m (Wallenstein et al., 1980; Ludbrook, 1998; McHugh, 2011). Wallenstein et al. (1980) first demonstrated that the Bonferroni procedure is preferable for general use because it provides critical values that are lower than those of other procedures when the number of comparisons can be limited and will be slightly larger than those of other procedures if many comparisons are made. Statistical analyses were performed with the aid of GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). F- and P-statistics associated with the ANOVA analyses of the data in Figures 1–5 are given in the respective figure legends.

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5

Results

L-CYSee infusion prevents physical dependence on morphine—36-h studies

The behavioral withdrawal phenomena elicited by the injection of NLX (1.5 mg/kg, IP) in rats that were receiving morphine (150 mg/kg, SC), plus a continuous infusion of the vehicle (saline, 20 μL/h, IV) or L-cysteine (20.8 μmol/kg/h, IV) or L-CYSee (20.8 μmol/kg/h, IV) for 36 h are shown in Figure 1. As can be seen, the injection of NLX to rats receiving the infusion of the vehicle elicited substantial increases in jumping behavior (jumps), wet-dog shakes (WDS), rearing behavior (rears), fore-paw licking (FPL), circling behavior (circles), full-body writhing (writhes), and sneezing (sneezes). These responses were similar in magnitude in rats that were receiving an infusion of L-cysteine. In contrast, NLX-precipitated phenomena (except for sneezing) were dramatically diminished in rats that were receiving the continuous infusion of L-CYSee. In addition, the NLX-precipitated withdrawal signs were fully expressed in rats that were receiving an infusion of L-SERee (Table 1). Note that we did not pursue L-SERee studies to see whether it affected the expression of apneic events, and elevations in MAP and heart rate elicited by the injection of NLX.

The increases in apneic events and elevations in MAP and heart rate, elicited by the injection of NLX (1.5 mg/kg) in rats that were receiving morphine (150 mg/kg, SC) and continuous infusion of vehicle or L-cysteine or L-CYSee are summarized in Figure 2. The injection of NLX in rats that were receiving the vehicle elicited substantial increases in the number of apneas and increases in MAP (sustained hypertension) and in heart rate (HR, tachycardia). These NLX-precipitated events were similar in magnitude in the rats that were receiving the infusion of L-cysteine. In contrast, the NLX-precipitated withdrawal phenomena were markedly reduced in rats receiving continuous infusion of L-CYSee. Actual values for MAP and heart rate before and after injection of NLX in morphine-treated rats receiving infusions of vehicle, L-cysteine, or L-CYSee are shown in Supplementary Table S1. Resting MAP and heart rate values before the injection of NLX were similar in the three groups of rats.

The changes in body temperatures and body weights elicited by the injection of NLX (1.5 mg/kg) in rats that were receiving morphine (150 mg/kg, SC) for 36 h, and continuous infusion of vehicle or L-cysteine or L-CYSee are summarized in Figure 3. The injection of NLX elicited marked decreases in body temperatures and body weights that were similar in magnitude in rats receiving infusion of vehicle or L-cysteine. The NLX-induced responses were markedly smaller in the rats that were receiving an infusion of L-CYSee. Actual body temperatures and body weights before and after injection of NLX in rats receiving morphine for 36 hours with co-infusions of vehicle, L-cysteine, or L-CYSee are shown in Supplementary Table S2. Resting body temperature and body weight values before the injection of NLX were similar in the three groups of rats. After 36 h of morphine treatment, body temperatures were elevated by just over 0.5°C in rats receiving infusions of vehicle or L-cysteine. Body temperature was not increased in rats receiving L-CYSee. The injection of NLX elicited substantial decreases in body temperatures and body weights in the vehicle- or L-cysteine-infusion groups, and much smaller responses in the rats receiving the infusion of L-CYSee.

L-CYSee reversal of physical dependence on morphine—48-h studies

The behavioral withdrawal phenomena elicited by the injection of NLX (1.5 mg/kg, IP) in rats that were receiving morphine (150 mg/kg, SC) for 48 h plus a continuous infusion of the vehicle (saline, 20 μL/h, IV) or L-cysteine (20.8 μmol/kg/h, IV) or L-CYSee (20.8 μmol/kg/h, IV) beginning after 36 h are shown in Figure 4. The injection of NLX into rats receiving the vehicle infusion elicited substantial increases in withdrawal behaviors. These responses were similar in magnitude in rats receiving infusion of L-cysteine, whereas withdrawal phenomena (except for sneezing) were dramatically diminished in rats receiving infusion of L-CYSee for 12 h. NLX-precipitated withdrawal signs in rats receiving an infusion of L-SERee were similar to those receiving infusion of vehicle (Table 1).

The increases in apneic events and elevations in MAP and heart rate, elicited by the injection of NLX (1.5 mg/kg, IP) in rats receiving morphine (150 mg/kg, SC) for 48 h and continuous infusion of vehicle or L-cysteine or L-CYSee beginning at 36 h are shown in Figure 5. NLX elicited substantial increases in apneas and elevations in MAP (hypertension) and in heart rate (HR, tachycardia) in rats receiving infusion of vehicle, and similar responses in rats receiving infusion of L-cysteine. In contrast, NLX-precipitated withdrawal phenomena were markedly reduced in rats receiving L-CYSee infusion. Actual values for MAP and heart rate before and after the injection of NLX in morphine-treated rats receiving infusion of vehicle, L-cysteine, or L-CYSee are shown in Supplementary Table S3. Resting MAP and heart rate values before the injection of NLX were similar in the three groups.

The changes in body temperatures and body weights elicited by the injection of NLX (1.5 mg/kg) in rats receiving morphine (150 mg/kg, SC) and infusion of vehicle or L-cysteine or L-CYSee that began 36 h after morphine administration and lasted for 12 h are summarized in Figure 3. The injection of NLX elicited pronounced decreases in body temperatures and body weights that were similar in magnitude in rats receiving vehicle or L-cysteine. These withdrawal responses were markedly smaller in rats receiving L-CYSee. Full details of the body temperatures and body weight before and after injection of NLX in these morphine-treated rats that were receiving infusions of vehicle, L-cysteine, or L-CYSee are shown in Supplementary Table S4. Resting body temperature and body weight values before the injection of NLX were similar in the three groups of rats. After 48 h of morphine treatment, body temperatures were elevated by just over 0.5°C in rats receiving infusions of vehicle or L-cysteine. The body temperatures were not elevated in rats receiving the infusion of L-CYSee. Body weights were similar in all three groups. The injection of NLX elicited substantial decreases in body temperatures and body weights in the vehicle- or L-cysteine-infusion groups, and much smaller responses in the rats receiving infusion of L-CYSee.

Discussion

The first set of major observations of this study was that co-infusion of the L-thiol ester, L-CYSee, markedly reduced the expression of multiple withdrawal signs (behavioral, cardiorespiratory, body weight loss, and hypothermia) elicited by the injection of the opioid receptor antagonist, NLX, in male Sprague Dawley rats treated for 36 h with slow-release morphine emulsion. The behavioral withdrawal signs indicative of the rats having become physically dependent on morphine, such as jumping, wet-dog shakes, rearing, fore-paw licking, circling, writhing, and sneezing (rapid expulsions of air), as well as decreases in body weight and body temperature, were consistent with previous reports published using this same slow-release morphine model (Lee and Fennessy, 1970; Laska and Fennessy, 1976; Laska and Fennessy, 1977; Laska and Fennessy, 1978; Lewis et al., 1988b), and with a wide variety of other administration protocols used to induce morphine dependence (Hutchinson et al., 2007; Lopez-Gimenez and Milligan, 2010; Morgan and Christie, 2011; Nielsen and Kreek, 2012). The increases in MAP and heart rate elicited by NLX are new findings in our morphine-dependence model, but are in full agreement with evidence that NLX-precipitated withdrawal is associated with hypertension and tachycardia in experimental animals (Buccafusco, 1983; Buccafusco, 1990; Buccafusco et al., 1984; Marshall and Buccafusco, 1985; Dixon and Chang, 1988; Chang and Dixon, 1990; Delle et al., 1990; Baraban et al., 1993) and humans (Newlin et al., 1992; Purssell et al., 1995; Walsh et al., 2003; Levin et al., 2019; Balshaw et al., 2021; Isoardi et al., 2022; Lee et al., 2022). This is due to globalized activation of the sympathetic nervous system. Finally, our finding that NLX elicited a substantial increase in apneic events is new to our morphine-dependence model, but also consistent with findings in rats (Baraban et al., 1993; Baldo, 2022) and humans (Schwarzer et al., 2015; Zamani et al., 2020; Wilson et al., 2023). The inability of L-cysteine to modify the NLX-precipitated withdrawal phenomena certainly suggests that the efficacy of L-CYSee involves the entry of this cell-penetrant L-thiol ester (Goto et al., 1983; Hisadome et al., 1986a; Hisadome et al., 1986b; Hisadome et al., 1988; Servin et al., 1988; Hisadome et al., 1990; Schöneich et al., 1992; Hobbs et al., 1993; Fukui et al., 1994; Ding and Demple, 1998; Galanakis et al., 2004; Mosier-Boss and Lieberman, 2005; Perissinotti et al., 2005; Defonsi Lestard et al., 2013; Mendoza et al., 2013; Arias et al., 2019; Lewis et al., 2022) into neurons involved in the acquisition of physical dependence/addiction on morphine (Laschka et al., 1976a; Laschka et al., 1976b; Laschka and Herz, 1977; Koob, 1987; Saiepour et al., 2001; Glass, 2010; Gardner, 2011; Glass, 2011). Moreover, the inability of L-SERee to prevent the acquisition of physical dependence on morphine indicates that the sulfur atom is vital to the ability of L-CYSee to prevent the intracellular processes within the brain by which morphine induces physical dependence (Deslandes et al., 2002; Gardner, 2011; Koob and Volkow, 2016; Volkow et al., 2019; Koob, 2020; Sakloth et al., 2020).

At present, we do not know how L-CYSee prevents the development of physical dependence on morphine. The mechanisms by which L-thiol esters exert their biological effects are likely to be multi-factorial and possibly include 1) direct binding of L-CYSee to plasma membrane/intracellular proteins, such as ion channels, receptors, and enzymes that alter the activities of the proteins by mechanisms not associated with the changes in the redox status of the proteins; 2) formation of thiol adducts, such as D-glucose-L-cysteine (Wróbel et al., 1997; Szwergold, 2006; Li et al., 2015) and mixed disulfides (Wilcken and Gupta, 1979; Lash and Jones, 1985; Turell, et al., 2013) in the blood; 3) modulation of redox status (e.g., reduction in L-cystine to L-cysteine), and the activity of plasma membrane proteins, such as Kv_1.2 K⁺-channels (Baronas et al., 2017), and after entry into cells, redox modulation of functional intracellular proteins (Bogeski et al., 2011; Bogeski and Niemeyer, 2014; O-Uchi et al., 2014; Gamper and Ooi, 2015; Gao et al., 2017; Garcia et al., 2018); 4) formation of S-thiolated proteins, such as S-cysteinylated, S-cysteinylglycinylated, and S-glutathionylated proteins, in plasma membranes of cells (Winkler et al., 2007; Rossi et al., 2009; Auclair et al., 2013; Belcastro et al., 2017; Ghezzi and Chan, 2017; Bonifácio et al., 2021); 5) conversion of L-CYSee to L-cysteine by membrane-associated esterases (Butterworth et al., 1993; Nishida et al., 1996), which then enters into multiple metabolic pathways including those that generate hydrogen sulfide via the sequential actions of L-cysteine aminotransferase and cystathionine γ-lyase in peripheral and central tissues (Kimura, 2014; Kimura, 2017; Bełtowski, 2019), including the carotid bodies (Prabhakar, 2012); 6) conversion of L-thiol esters to cysteine sulfenic, sulfinic, and sulfonic via cysteine dioxygenase (Yamaguchi and Hosokawa, 1987; Joseph and Maroney, 2007; Stipanuk et al., 2009; Stipanuk et al., 2011); and 7) formation of S-nitroso-L-cysteine, an endogenous S-nitrosothiol (Myers et al., 1990; Bates et al., 1991; Seckler et al., 2020), with many substantial roles in intracellular signaling cascades (Lipton et al., 1993; Foster et al., 2009; Seth and Stamler, 2011; Stomberski et al., 2019; Gaston et al., 2020), including those controlling the cardiorespiratory function (Davisson et al., 1996; Davisson et al., 1997; Ohta et al., 1997; Lipton et al., 2001; Gaston et al., 2006; Lewis et al., 2006; Gaston et al., 2020) and those involved in the attenuation of opioid induced respiratory depression (OIRD) (Getsy et al., 2022a; Getsy et al., 2022b). Any or all of these mechanisms (and possibly those not mentioned) may interact with signaling pathways involved in the acquisition of physical dependence on opioids, such as morphine, and the expression of the NLX-precipitated withdrawal syndrome, including those involving N-methyl D-aspartate (NMDA) glutamatergic receptors (Buccafusco et al., 1995; Herman et al., 1995; Rasmussen, 1995; Noda and Nabeshima, 2004; Glass, 2011; Fluyau et al., 2020), muscarinic receptors (Marshall and Buccafusco, 1987; Holland et al., 1993), corticotropin-releasing factor (CRF) receptor (CRF1) (García-Carmona et al., 2015), tachykinin receptors (Michaud and Couture, 2003), voltage-gated Ca²⁺-channels (Tokuyama et al., 1995; Dogrul et al., 2002; Esmaeili-Mahani et al., 2008; Alboghobeish et al., 2019), adenylyl cyclase superactivation and opioid receptor phosphorylation (Avido-Reiss et al., 1996; Avido-Reiss et al., 1997; Wang et al., 1999; Eckhardt et al., 2000), oxidative stress (Xu et al., 2006; Mori et al., 2007; Abdel-Zaher et al., 2013; Mansouri et al., 2020; Ward et al., 2020; Houshmand et al., 2021), and the nitric oxide-cGMP signaling cascade (Adams et al., 1993; Cappendijk et al., 1993; Majeed et al., 1994; Vaupel et al., 1995a; Buccafusco et al., 1995; Vaupel et al., 1995b; Herman et al., 1995; Leza et al., 1995; 1996; London et al., 1995; Dambisya and Lee, 1996; Bhatt and Kumar, 2015; Tsakova et al., 2015; Sackner et al., 2019; Gledhill and Babey, 2021). Since L-CYSee blunted the expression of all NLX-precipitated behavioral (except for sneezing), physical (body weight loss and hypothermia), and cardiorespiratory (hypertension, tachycardia, and incidence of apneas) phenomena, it is tempting to assume that L-CYSee interrupts fundamental intracellular processes that are essential for the development of physical dependence on morphine.

The second set of novel findings was that the introduction of L-CYSee infusion 36 h into the morphine administration period appeared to reverse the established physical dependence on the opioid, as assessed at 48 h (i.e., within 12 h of giving continuous infusion of L-CYSee). Specifically, NLX-precipitated behavioral phenomena (except for sneezing), hypertension, tachycardia, apneas, hypothermia, and body weight loss were markedly fewer in the rats that had received L-CYSee for 12 h. Again, the lack of effect of L-cysteine and L-SERee suggests that the intracellular delivery of L-CYSee and its sulfur atom (and associated thiol chemistry) is essential to the ability of the L-thiol ester to reverse the established physical dependence on morphine. Again, the mechanism of action for how L-CYSee reverses physical dependence on morphine is not known, but any of the mechanisms discussed in the previous paragraph, including its potent antioxidant properties, may be involved. The well-known therapeutics and bioactive compounds that reverse established physical dependence include: L-histidine and certain histamine receptor sub-type agonists (Wong and Roberts, 1976), such as melatonin (Raghavendra and Kulkarni SK, 1999; Raghavendra and Kulkarni SK, 2000); the antioxidant, quercetin (Singh et al., 2002; Naidu et al., 2003); the serotonin-reuptake inhibitor, fluoxetine (Singh et al., 2003); the nitric oxide synthase inhibitor, L-N^G-nitroarginine methyl ester (Naidu et al., 2003; Sing et al., 2003); inhibitors of Ca²⁺/calmodulin-dependent protein kinase II (Wang et al., 2003; Tang et al., 2006); the β₂-AR antagonist, butoxamine (Liang et al., 2007); adrenomedullin receptor antagonists (Wang et al., 2011); the antipsychotic (dopamine D2 receptor antagonist), haloperidol (Yang et al., 2011); and positive allosteric modulators of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamatergic receptors (Hu et al., 2018). The mechanism(s) of action for how L-CYSee reverses established physical dependence on morphine is of great clinical relevance, and opens the way for future studies on this and other bioactive L,D-thiol esters and related compounds (Baby et al., 2021; Baby et al., 2021; Gaston et al., 2021; Jenkins et al., 2021; Getsy et al., 2022a; Getsy et al., 2022b; Getsy et al., 2022c; Getsy et al., 2022d; Getsy et al., 2022e; Getsy et al., 2022f; Lewis et al., 2022) with respect to their ability to reverse physical dependence on morphine and other opioids, including heroin and fentanyl.

Many questions remain regarding the potential use of L-thiol esters as therapeutics for key clinical problems associated with opioid analgesia in humans, including: 1) if L-CYSee attenuates/blocks self-administration of opioids in OUD patients, adding it to prescription opioids may result in lower drug abuse or addiction potential; 2) if L-CYSee attenuates or blocks development of physical dependence on opioids, then adding it to prescription opioids will minimize and may potentially eliminate physical dependence in individuals who receive opioids for a long-term basis, such as everyday, all day, for weeks/months; 3) if L-CYSee attenuates/blocks tachyphylaxis to opioid analgesia or hyperalgesia caused by opioids, then the addition of L-CYSee to prescription opioids will maintain their analgesic efficacy over long periods of time, eliminating the development of tolerance, need for escalating doses, and potential complications of hyperalgesia; 4) if L-CYSee has several of the advantageous effects observed in rodents, then adding it to opioid analgesics would multiply the beneficial aspects of the opioids; 5) if L-CYSee prevents the development of physical dependence, and specifically, if it is introduced to an individual with physical dependence and attenuates/blocks opioid withdrawal, it could be used as an outpatient/inpatient medication to manage opioid withdrawal in those who are iatrogenically physically dependent (long-term opioid prescriptions) or those who are addicted and physically dependent; 6) if L-CYSee attenuates/blocks euphoria and/or the development of physiological dependence to opioids, then it would be a good medication for medication-assisted treatment (MAT) and a potentially good drug for harm reduction interventions in people with OUD who are not interested in the psychosocial aspects of counseling and treatment; 7) as some patients with a history of OUD who are currently sober need opioids for the treatment of acute or chronic pain syndromes, this L-thiol ester, if it attenuates or blocks euphoria and physical dependence, could be added to opioid analgesics when given to people with a history of OUD, thereby eliminating the risk of opioid analgesic-precipitating euphoria, drug cravings, and their markedly increased risk of relapse; 8) if L-CYSee attenuates/blocks euphoria from chemically mediated dopamine surges within the ventral tegmentum, nucleus accumbens, or medial prefrontal cortex, where brain rewarding euphoria-producing dopamine surge happens from all drugs of abuse/addiction (Deslandes et al., 2002; Gardner, 2011; Koob and Volkow, 2016; Volkow et al., 2019; Koob, 2020; Sakloth et al., 2020), then it will be useful in the treatment of OUD and other SUDs; and 9) if L-CYSee attenuates/blocks euphoria from chemically mediated dopamine surges, it could be combined with or added to all controlled prescription drugs, resulting in an abuse-resistant or non-abusable form of prescribed opioids, benzodiazepines, and psychostimulants. In relation to point (1), we recently showed that co-administration of the D-isomer, D-cysteine ethyl ester, with fentanyl prevents the development of fentanyl-induced conditioned place preference in both male and female rats (Knauss et al., 2023). Thus, L,D-thiol esters likely reduce the rewarding properties of opioids and reduce their addictive potential.

A final caveat to translating these findings to humans lies in the genetic variation of humans (e.g., 5–6 million SNPs between any two individuals) in comparison to the total variation found in the outbred Sprague Dawley rats tested here (Gileta et al., 2022). This lack of genetic variation in preclinical models is one explanation for the inability of many findings to translate across species (Garner, 2014; Zuberi and Lutz, 2016). The pharmacogenetics of opioids have been studied, and numerous pharmacokinetic molecules, such as COMT, OPRM1, CYP2D6, and ABCB1, have been identified that are useful in clinical application (Owusu Obeng et al., 2017). In animal models, opioid withdrawal specifically has been studied using the C57BL/6J x DBA2 recombinant inbred lines, where a locus on chromosome 16 was identified as affecting the locomotor behavior of naloxone-precipitated withdrawal (Philip et al., 2010). In another population, 129 × C57BL/6 cross-identified loci on chromosomes 1, 5, and 10 were involved in withdrawal jumping frequencies (Kest et al., 2004). Testing the efficacy of drugs using a population of outbred mice containing approximately 45 million segregating SNPs, such as the diversity outbred mice (Saul et al., 2019), will increase the likelihood that the drug will translate within species before traversing across species.

Study limitations

A limitation of the present study is that we have not examined the efficacy of lower doses of L-CYSee to prevent or reverse morphine-induced physical dependence. Finding out the lower limit is key to minimizing potential adverse biological effects that were not monitored in the present study. In particular, we have not determined whether the co-administration of L-CYSee alters the analgesic actions of morphine, although we have reported that L-CYSee (Lewis et al., 2022), L-cysteine methyl ester (Getsy et al., 2022a), and other thiolesters and related compounds (Baby et al., 2021; Baby et al., 2021; Gaston et al., 2021; Jenkins et al., 2021; Getsy et al., 2022b; Getsy et al., 2022c; Getsy et al., 2022d; Getsy et al., 2022e; Getsy et al., 2022f) prevent and/or reverse the actions of morphine and fentanyl on ventilatory parameters, arterial blood–gas chemistry, and alveolar-arterial gradient in freely-moving rats without compromising opioid-induced analgesia or sedation. Synthetic opioids, especially fentanyl, are playing a major and ever-increasing role in the current opioid crisis (Arendt, 2021; Deo et al., (2021), and future studies must determine whether L-CYSee can overcome and reverse physical dependence on fentanyl. A concern about the study protocol regarding the ability of L-CYSee to reverse established morphine dependence, was the short time (12 h) between the surgery to initiate the intravenous infusions (implantation of minipumps under isoflurane anesthesia), and the administration of NLX to precipitate withdrawal. Despite the robust nature of the NLX-induced responses in rats that received intravenous infusions of vehicle, L-cysteine, or L-SERee for 12 h, it is possible that the lingering effects of anesthesia affected the expression of the withdrawal phenomena. Another important limitation of our study is the lack of data about the efficacy of L-CYSee in preventing/reversing physical dependence in female rats. This is especially important because 1) opioids exert qualitatively and quantitatively different pharmacological (e.g., ventilation, analgesia) responses in females compared to males (Dahan et al., 1998; Sarton et al., 1998; Bodnar and Kest, 2010); 2) there are many sex-specific differences in opioid receptor signaling (Bryant et al., 2006; Hosseini et al., 2011); 3) pronounced sex differences in development of opioid hyperalgesia, tolerance and withdrawal (Bodnar and Kest, 2010); and 4) several major behavioral sex differences in the expression and treatment of OUDs (Huhn et al., 2019; Davis et al., 2021; Knouse and Briand, 2021). The lack of understanding about the molecular mechanisms by which L-CYSee affects the acquisition/reversal of morphine dependence is a limitation that needs to be addressed. In addition to potential direct interactions with yet to be defined functional proteins, potential mechanisms of action of L-CYSee may involve 1) direct binding to putative L,D-cysteine-binding protein, such as myristoylated alanine-rich C-kinase substrate (Semenza et al., 2021), 2) interruption of μ-OR-β-arrestin-coupled cell signaling processes to spare the antinociceptive G-protein-dependent actions of morphine (Schmid et al., 2017; Grim et al., 2020), and/or 3) potential conversion of L-CYSee to S-nitroso-L-CYSee or S-nitroso-L-cysteine by S-nitrosylation of the sulfur atom in L-thiol esters via processes requiring nitric oxide synthase (Perissinotti et al., 2005; Hess and Stamler, 2012; Stomberski et al., 2019; Seckler et al., 2020; Seckler et al., 2022), which may act via an intracellular penetrating mechanism(s) (Clancy et al., 2001). To test the possibility that L-CYSee elicits the production of S-nitrosylated versions of the L-thiol ester, we are determining whether intravenous injections of L-CYSee increase the production of S-nitrosylated species in the blood, peripheral tissues, and brain via the use of an ultra-sensitive capacitive sensor (Seckler et al., 2017), and whether such injections of L-CYSee increase the expression of NADPH diaphorase in the brain and peripheral structures, on the basis that NADPH diaphorase is used to visualize free S-nitrosothiols and S-nitrosylated proteins in aldehyde-treated tissue (Seckler et al., 2020). S-nitrosothiols, such as S-nitroso-L-cysteine and S-nitroso-L-glutathione, play important roles in ventilatory control processes in the brainstem, circulating red blood cells, and peripheral structures, such as the carotid bodies (Lipton et al., 2001; Gaston et al., 2006; Palmer et al., 2013; Gaston et al., 2014; Palmer et al., 2015; Gaston et al., 2020). The possibility that the conversion of L-CYSee to S-nitroso-L-CYSee is responsible for the effects observed in this study would add to our understanding of the pharmacology of L–S-nitrosothiols (Davisson et al., 1996; Lewis et al., 1996; Travis et al., 1996; Davisson et al., 1997; Travis et al., 1997; Lewis et al., 2005; Gaston et al., 2006; Lewis et al., 2006; Gaston et al., 2020). Another limitation that certainly needs addressing is our lack of information about the blood and tissue distribution resulting from the infusion of L-CYSee in the presence or absence of morphine, although L-CYSee can be readily detected in plasma, and peripheral and central tissues upon acute administration to naïve rats (Servin et al., 1998). We intend to perform pharmacokinetics analyses of L-CYSee distribution in brain regions involved in the acquisition of opioid dependence, such as the medial prefrontal cortex (Deslandes et al., 2002; Gardner, 2011; Koob and Volkow, 2016; Volkow et al., 2019; Koob, 2020; Sakloth et al., 2020), using our liquid chromatography–mass spectrometry methodology (Altawallbeh et al., 2019).

Conclusion

This study demonstrates that systemic infusion of the membrane-permeable L-thiol ester, L-CYSee, prevents the development of physical dependence on morphine in male Sprague Dawley rats by mechanisms dependent on thiol biochemistry. In addition, this study demonstrates that L-CYSee reverses established dependence on morphine in rats also by thiol-dependent processes. Delineating the exact thiol-dependent signaling pathways will add greatly to our understanding of the processes by which opioids induce dependence, and how the bioactive L-thiol esters exert their effects. Our study was spurred by the ground-breaking work of Trivedi, Deth, and others, which added greatly to our understanding of the mechanisms that opioids cause physical dependence and psychological addiction (Trivedi et al., 2014; Trivedi and Deth, 2015; Trivedi et al., 2015). Their evidence that morphine may cause dependence/addiction by blocking the entry of L-cysteine into neurons inhibiting the EAA3/EAAC1 transporters (Trivedi et al., 2014) prompted our studies with the membrane-permeable, L-thiol ester, L-CYSee. The findings that L-CYSee markedly reduced the majority of NLX-precipitated withdrawal phenomena suggests that decreased levels of L-cysteine entry into cells plays a key role in establishing physical dependence on morphine. The lone withdrawal phenomenon that was not ameliorated by L-CYSee was sneezing, a key feature of the opioid withdrawal response in humans (Ostrea et al., 1975; Specker et al., 1998; Gaalema et al., 2012; Lofwall et al., 2013) and experimental animals (Hendrie, 1985; Liu et al., 2007; Singh et al., 2015). We are currently trying to understand the current state of knowledge about the neural mechanisms responsible for sneezing (Batsel and Lines, 1975; Undem et al., 2000; Li et al., 2021; Ramirez et al., 2022) to see if that can give insights into the signaling pathways that are/are not involved in the actions of L-CYSee. The present findings add to our knowledge about the efficacy of L,D-thiol esters, such as L-CYSee (Lewis et al., 2022) L-GSHee (Jenkins et al., 2021), D-CYSee (Getsy et al., 2022c; Getsy et al., 2022d), D-cystine di(m)ethyl ester (Gaston et al., 2021), and the free radical-superoxide anion scavenger, Tempol (Baby et al., 2021a; Baby et al., 2021b), on the pharmacological actions of opioids.

References

• 1

  Abdel-ZaherA. O.MostafaM. G.FarghalyH. S.HamdyM. M.Abdel-HadyR. H. (2013). Role of oxidative stress and inducible nitric oxide synthase in morphine-induced tolerance and dependence in mice. Effect of alpha-lipoic acid. Behav. Brain Res.247, 17–26. 10.1016/j.bbr.2013.02.034

  • CrossRef
  • Google Scholar

• 2

  AdamsM. L.KalickiJ. M.MeyerE. R.CiceroT. J. (1993). Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester. Life Sci.52, PL245–PL249. 10.1016/0024-3205(93)90472-f

  • CrossRef
  • Google Scholar

• 3

  AlboghobeishS.NaghizadehB.KheirollahA.GhorbanzadehB.MansouriM. T. (2019). Fluoxetine increases analgesic effects of morphine, prevents development of morphine tolerance and dependence through the modulation of L-type calcium channels expression in mice. Behav. Brain Res.361, 86–94. 10.1016/j.bbr.2018.12.020

  • CrossRef
  • Google Scholar

• 4

  AltawallbehG.SmithL.LewisS. J.AuthierS.BujoldK.GastonB.et al (2019). Pharmacokinetic study of Sudaxine in dog plasma using novel LC-MS/MS method. Drug Test. Anal.11, 403–410. 10.1002/dta.2507

  • CrossRef
  • Google Scholar

• 5

  Alvarez-PerezB.PorasH.MaldonadoR. (2023). The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: a novel possible therapeutic approach for opioid use disorders. Br. J. Pharmacol.180, 879–893. 10.1111/bph.15656

  • CrossRef
  • Google Scholar

• 6

  ArendtF. (2021). The opioid-overdose crisis and fentanyl: the role of online information seeking via internet search engines. Health Commun.36, 1148–1154. 10.1080/10410236.2020.1748820

  • CrossRef
  • Google Scholar

• 7

  AriasJ. M.DíazS. B.Ben AltabefA.DupuyF. G. (2019). Interaction of cysteine and its derivatives with monolayers of dipalmitoylphosphatidylcholine. Colloids Surf. B Biointerfaces184, 110548. 10.1016/j.colsurfb.2019.110548

  • CrossRef
  • Google Scholar

• 8

  AuclairJ. R.BrodkinH. R.D'AquinoJ. A.PetskoG. A.RingeD.AgarJ. N. (2013). Structural consequences of cysteinylation of Cu/Zn-superoxide dismutase. Biochemistry52, 6145–6150. 10.1021/bi400613h

  • CrossRef
  • Google Scholar

• 9

  Avidor-ReissT.NevoI.LevyR.PfeufferT.VogelZ. (1996). Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J. Biol. Chem.271, 21309–21315. 10.1074/jbc.271.35.21309

  • CrossRef
  • Google Scholar

• 10

  Avidor-ReissT.NevoI.SayaD.BayewitchM.VogelZ. (1997). Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J. Biol. Chem.272, 5040–5047. 10.1074/jbc.272.8.5040

  • CrossRef
  • Google Scholar

• 11

  BabyM. S.DiscalaF. G.GruberR.GetsyM. P.ChengF.DamronS. D.et al (2021a). Tempol reverses the negative effects of morphine on arterial blood-gas chemistry and tissue oxygen saturation in freely-moving rats. Front. Pharmacol.12, 749084. 10.3389/fphar.2021.749084

  • CrossRef
  • Google Scholar

• 12

  BabyS. M.GruberR.DiscalaJ.PuskovicV.JoseN.ChengF.et al (2021b). Systemic administration of Tempol attenuates the cardiorespiratory depressant effects of fentanyl. Front. Pharmacol.12, 690407. 10.3389/fphar.2021.690407

  • CrossRef
  • Google Scholar

• 13

  BalanaserM.CarleyM.BaronR.FinnerupN. B.MooreR. A.RowbothamM. C.et al (2023). Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. Pain164, 230–251. 10.1097/j.pain.0000000000002688

  • CrossRef
  • Google Scholar

• 14

  BaldoB. A. (2022). Current research in pathophysiology of opioid-induced respiratory depression, neonatal opioid withdrawal syndrome, and neonatal antidepressant exposure syndrome. Curr. Res. Toxicol.3, 100078. 10.1016/j.crtox.2022.100078

  • CrossRef
  • Google Scholar

• 15

  BalshawR.RoweA.CochraneC. K.NgB.JiangA.RisiA.et al (2021). Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin. Toxicol. (Phila).59, 38–46. 10.1080/15563650.2020.1758325

  • CrossRef
  • Google Scholar

• 16

  BarabanS. C.StornettaR. L.GuyenetP. G. (1993). Respiratory control of sympathetic nerve activity during naloxone-precipitated morphine withdrawal in rats. J. Pharmacol. Exp. Ther.265, 89–95.

  • Google Scholar

• 17

  BaronasV. A.YangR. Y.KurataH. T. (2017). Extracellular redox sensitivity of Kv1.2 potassium channels. Sci. Rep.7, 9142. 10.1038/s41598-017-08718-z

  • CrossRef
  • Google Scholar

• 18

  BatesJ. N.HarrisonD. G.MyersP. R.MinorR. L. (1991). EDRF: nitrosylated compound or authentic nitric oxide. Basic Res. Cardiol.86, 17–26. 10.1007/978-3-642-72461-9_3

  • CrossRef
  • Google Scholar

• 19

  BatselH. L.LinesA. J. (1975). Neural mechanisms of sneeze. Am. J. Physiol.229, 770–776. 10.1152/ajplegacy.1975.229.3.770

  • CrossRef
  • Google Scholar

• 20

  BecharaA.BerridgeK. C.BickelW. K.MorónJ. A.WilliamsS. B.SteinJ. S. (2019). A neurobehavioral approach to addiction: implications for the opioid epidemic and the psychology of addiction. Psychol. Sci. Public Interest20, 96–127. 10.1177/1529100619860513

  • CrossRef
  • Google Scholar

• 21

  BelcastroE.GaucherC.CortiA.LeroyP.LartaudI.PompellaA. (2017). Regulation of protein function by S-nitrosation and S-glutathionylation: processes and targets in cardiovascular pathophysiology. Biol. Chem.398, 1267–1293. 10.1515/hsz-2017-0150

  • CrossRef
  • Google Scholar

• 22

  BełtowskiJ. (2019). Synthesis, metabolism, and signaling mechanisms of hydrogen sulfide: an overview. Methods Mol. Biol.2007, 1–8. 10.1007/978-1-4939-9528-8_1

  • CrossRef
  • Google Scholar

• 23

  BenyaminR.TrescotA. M.DattaS.BuenaventuraR.AdlakaR.SehgalN.et al (2008). Opioid complications and side effects. Pain Physician11 (2 Suppl. l), S105–S120. 10.36076/ppj.2008/11/s105

  • CrossRef
  • Google Scholar

• 24

  BhattK.KumarA. (2015). Mechanism of morphine addiction by inhibiting the soluble Guanylate Cyclase-Nitric Oxide (sGC-NO) pathway. Math. Biosci.266, 85–92. 10.1016/j.mbs.2015.06.004

  • CrossRef
  • Google Scholar

• 25

  BiancuzziH.Dal MasF.BresciaV.CampostriniS.CascellaM.CuomoA.et al (2023). Opioid misuse: a review of the Main issues, challenges, and strategies. Int. J. Environ. Res. Public Health19, 11754. 10.3390/ijerph191811754

  • CrossRef
  • Google Scholar

• 26

  BodnarR. J.KestB. (2010). Sex differences in opioid analgesia, hyperalgesia, tolerance and withdrawal: central mechanisms of action and roles of gonadal hormones. Horm. Behav.58, 72–81. 10.1016/j.yhbeh.2009.09.012

  • CrossRef
  • Google Scholar

• 27

  BogeskiI.KapplR.KummerowC.GulaboskiR.HothM.NiemeyerB. A. (2011). Redox regulation of calcium ion channels: chemical and physiological aspects. Cell Calcium50, 407–423. 10.1016/j.ceca.2011.07.006

  • CrossRef
  • Google Scholar

• 28

  BogeskiI.NiemeyerB. A. (2014). Redox regulation of ion channels. Antioxid. Redox Signal.21, 859–862. 10.1089/ars.2014.6019

  • CrossRef
  • Google Scholar

• 29

  BonifácioV. D. B.PereiraS. A.SerpaJ.VicenteJ. B. (2021). Cysteine metabolic circuitries: druggable targets in cancer. Br. J. Cancer124, 862–879. 10.1038/s41416-020-01156-1

  • CrossRef
  • Google Scholar

• 30

  BrognaraF.DiasD. P.CastaniaJ. A.FazanR.JrLewisS. J.SalgadoH. C. (2016). Cardiovascular responses elicited by continuous versus intermittent electrical stimulation of the aortic depressor nerve in conscious rats. Life Sci.148, 99–105. 10.1016/j.lfs.2016.02.033

  • CrossRef
  • Google Scholar

• 31

  BrowneC. J.GodinoA.SaleryM.NestlerE. J. (2020). Epigenetic mechanisms of opioid addiction. Biol. Psychiatry87, 22–33. 10.1016/j.biopsych.2019.06.027

  • CrossRef
  • Google Scholar

• 32

  BryantC. D.EitanS.SinchakK.FanselowM. S.EvansC. J. (2006). NMDA receptor antagonism disrupts the development of morphine analgesic tolerance in male, but not female C57BL/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.291, R315–R326. 10.1152/ajpregu.00831.2005

  • CrossRef
  • Google Scholar

• 33

  BuccafuscoJ. J. (1983). Cardiovascular changes during morphine withdrawal in the rat: effects of clonidine. Pharmacol. Biochem. Behav.18, 209–215. 10.1016/0091-3057(83)90365-9

  • CrossRef
  • Google Scholar

• 34

  BuccafuscoJ. J. (1990). Participation of different brain regions in the anti-narcotic withdrawal action of clonidine in the dependent rat. Brain Res.513, 8–14. 10.1016/0006-8993(90)91083-s

  • CrossRef
  • Google Scholar

• 35

  BuccafuscoJ. J.MarshallD. C.TurnerR. M. (1984). A comparison of the inhibitory effects of clonidine and guanfacine on the behavioral and autonomic components of morphine withdrawal in rats. Life Sci.35, 1401–1408. 10.1016/0024-3205(84)90398-9

  • CrossRef
  • Google Scholar

• 36

  BuccafuscoJ. J.TerryA. V.ShusterL. (1995). Spinal NMDA receptor - nitric oxide mediation of the expression of morphine withdrawal symptoms in the rat. Brain Res.679, 189–199. 10.1016/0006-8993(95)00203-3

  • CrossRef
  • Google Scholar

• 37

  ButterworthM.UpshallD. G.CohenG. M. (1993). A novel role for carboxylesterase in the elevation of cellular cysteine by esters of cysteine. Biochem. Pharmacol.46, 1131–1137. 10.1016/0006-2952(93)90460-e

  • CrossRef
  • Google Scholar

• 38

  CappendijkS. L.de VriesR.DzoljicM. R. (1993). Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Neurosci. Lett.162, 97–100. 10.1016/0304-3940(93)90569-7

  • CrossRef
  • Google Scholar

• 39

  ChangA. P.DixonW. R. (1990). Role of plasma catecholamines in eliciting cardiovascular changes seen during naloxone-precipitated withdrawal in conscious, unrestrained morphine-dependent rats. J. Pharmacol. Exp. Ther.254, 857–863.

  • Google Scholar

• 40

  ChartoffE. H.ConneryH. S. (2014). It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front. Pharmacol.5, 116. 10.3389/fphar.2014.00116

  • CrossRef
  • Google Scholar

• 41

  ChristieM. J. (2008). Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Brit J. Pharmacol.154, 384–396. 10.1038/bjp.2008.100

  • CrossRef
  • Google Scholar

• 42

  ClancyR.CederbaumA. I.StoyanovskyD. A. (2001). Preparation and properties of S-nitroso-L-cysteine ethyl ester, an intracellular nitrosating agent. J. Med. Chem.44, 2035–2038. 10.1021/jm000463f

  • CrossRef
  • Google Scholar

• 43

  CollierH. O. J.FrancisD. L.SchneiderC. (1972). Modification of morphine withdrawal by drugs interacting with humoral mechanisms: some contradictions and their interpretation. Nature237, 220–223. 10.1038/237220a0

  • CrossRef
  • Google Scholar

• 44

  DahanA.SartonE.TeppemaL.OlievierC. (1998). Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology88, 903–913. 10.1097/00000542-199804000-00009

  • CrossRef
  • Google Scholar

• 45

  DaijoH.KaiS.TanakaT.WakamatsuT.KishimotoS.SuzukiK.et al (2011). Fentanyl activates hypoxia-inducible factor 1 in neuronal SH-SY5Y cells and mice under non-hypoxic conditions in a μ-opioid receptor-dependent manner. Eur. J. Pharmacol.667, 144–152. 10.1016/j.ejphar.2011.06.014

  • CrossRef
  • Google Scholar

• 46

  DambisyaY. M.LeeT. L. (1996). Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br. J. Pharmacol.117, 914–918. 10.1111/j.1476-5381.1996.tb15280.x

  • CrossRef
  • Google Scholar

• 47

  DavisJ. P.EddieD.PrindleJ.DworkinE. R.ChristieN. C.SabaS.et al (2021). Sex differences in factors predicting post-treatment opioid use. Addiction116, 2116–2126. 10.1111/add.15396

  • CrossRef
  • Google Scholar

• 48

  DavissonR. L.BatesJ. N.JohnsonA. K.LewisS. J. (2014). Effects of intracerebroventricular injections of 5-HT on systemic vascular resistances of conscious rats. Microvasc. Res.95C, 116–123. 10.1016/j.mvr.2014.08.002

  • CrossRef
  • Google Scholar

• 49

  DavissonR. L.TravisM. D.BatesJ. N.JohnsonA. K.LewisS. J. (1997). Stereoselective actions of S-nitrosocysteine in central nervous system of conscious rats. Am. J. Physiol.272, H2361–H2368. 10.1152/ajpheart.1997.272.5.H2361

  • CrossRef
  • Google Scholar

• 50

  DavissonR. L.TravisM. D.BatesJ. N.LewisS. J. (1996). Hemodynamic effects of L- and D-S-nitrosocysteine in the rat. Stereoselective S-nitrosothiol recognition sites. Circ. Res.79, 256–262. 10.1161/01.res.79.2.256

  • CrossRef
  • Google Scholar

• 51

  Defonsi LestardM. E.DíazS. B.PuiattiM.EcheverríaG. A.PiroO. E.PieriniA. B.et al (2013). Vibrational and structural behavior of (L)-cysteine ethyl ester hydrochloride in the solid state and in aqueous solution. J. Phys. Chem. A117, 14243–14252. 10.1021/jp409252d

  • CrossRef
  • Google Scholar

• 52

  DelleM.RickstenS. E.HäggendalJ.OlssonK.SkarphedinssonJ. O.ThorénP. (1990). Regional changes in sympathetic nerve activity and baroreceptor reflex function and arterial plasma levels of catecholamines, renin and vasopressin during naloxone-precipitated morphine withdrawal in rats. J. Pharmacol. Exp. Ther.253, 646–654.

  • Google Scholar

• 53

  DeoV. S.GilsonT. P.KasparC.SingerM. E. (2021). The fentanyl phase of the opioid epidemic in Cuyahoga County, Ohio, United States. J. Forensic Sci.66, 926–933. 10.1111/1556-4029.14665

  • CrossRef
  • Google Scholar

• 54

  DeslandesP. N.PacheD. M.SewellR. D. (2002). Drug dependence: neuropharmacology and management. J. Pharm. Pharmacol.54, 885–895. 10.1211/002235702760088992

  • CrossRef
  • Google Scholar

• 55

  DingH.DempleB. (1998). Thiol-mediated disassembly and reassembly of [2Fe-2S] clusters in the redox-regulated transcription factor SoxR. Biochem.37, 17280–17286. 10.1021/bi980532g

  • CrossRef
  • Google Scholar

• 56

  DixonW. R.ChangA. P. (1988). Effect of phentolamine on blood pressure, heart rate and plasma catecholamine levels in conscious, unrestrained morphine dependent rats during naloxone precipitated autonomic withdrawal responses. Proc. West Pharmacol. Soc.31, 117–119.

  • Google Scholar

• 57

  DogrulA.ZagliU.TulunayF. C. (2002). The role of T-type calcium channels in morphine analgesia, development of antinociceptive tolerance and dependence to morphine, and morphine abstinence syndrome. Life Sci.71, 725–734. 10.1016/s0024-3205(02)01736-8

  • CrossRef
  • Google Scholar

• 58

  DydykA. M.SizemoreD. C.HaddadL. M.LindsayL.PorterB. R. (2023). “NP safe prescribing of controlled substances while avoiding drug diversion,” in StatPearls (Treasure Island (FL): StatPearls Publishing). PMID: 33232099.

  • Google Scholar

• 59

  DydykA. M.SizemoreD. C.SmockW.DulebohnS. C.PorterB. R. (2022). “Kentucky KASPER and controlled substance prescribing,” in StatPearls (Treasure Island (FL): StatPearls Publishing). PMID: 33620803.

  • Google Scholar

• 60

  EckhardtK.NevoI.LevyR.MikusG.EichelbaumM.VogelZ. (2000). Morphine-related metabolites differentially activate adenylyl cyclase isozymes after acute and chronic administration. FEBS Lett.470, 309–314. 10.1016/s0014-5793(00)01329-6

  • CrossRef
  • Google Scholar

• 61

  Esmaeili-MahaniS.FathiY.MotamediF.HosseinpanahF.AhmadianiA. (2008). L-type calcium channel blockade attenuates morphine withdrawal: in vivo interaction between L-type calcium channels and corticosterone. Horm. Behav.53, 351–357. 10.1016/j.yhbeh.2007.10.012

  • CrossRef
  • Google Scholar

• 62

  FluyauD.RevadigarN.PierreC. G. (2020). Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: a systematic review. Drug Alcohol Depend.208, 107845. 10.1016/j.drugalcdep.2020.107845

  • CrossRef
  • Google Scholar

• 63

  FosterM. W.HessD. T.StamlerJ. S. (2009). Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med.15, 391–404. 10.1016/j.molmed.2009.06.007

  • CrossRef
  • Google Scholar

• 64

  FrankebergerJ.JarlenskiM.KransE. E.CoulterR. W. S.MairC. (2023). Opioid use disorder and overdose in the first year postpartum: a rapid scoping review and implications for future research. Matern. Child. Health J.27, 1140–1155. 10.1007/s10995-023-03614-7

  • CrossRef
  • Google Scholar

• 65

  FukuiK.KanedaM.TakahashiE.WashioM.DoiK. (1994). Protective effects of sulfhydryl compounds on HOCl-induced intracellular Ca2+ increase in single rat ventricular myocytes. J. Mol. Cell Cardiol.26, 455–461. 10.1006/jmcc.1994.1056

  • CrossRef
  • Google Scholar

• 66

  GaalemaD. E.ScottT. L.HeilS. H.CoyleM. G.KaltenbachK.BadgerG. J.et al (2012). Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates. Addiction107, 53–62. 10.1111/j.1360-0443.2012.04039.x

  • CrossRef
  • Google Scholar

• 67

  GalanakisD.KourounakisA. P.TsiakitzisK. C.DoulgkerisC.RekkaE. A.GavalasA.et al (2004). Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity. Bioorg Med. Chem. Lett.14, 3639–3643. 10.1016/j.bmcl.2004.05.025

  • CrossRef
  • Google Scholar

• 68

  GamperN.OoiL. (2015). Redox and nitric oxide-mediated regulation of sensory neuron ion channel function. Antioxid. Redox Signal22, 486–504. 10.1089/ars.2014.5884

  • CrossRef
  • Google Scholar

• 69

  GaoL.González-RodríguezP.Ortega-SáenzP.López-BarneoJ. (2017). Redox signaling in acute oxygen sensing. Redox Biol.12, 908–915. 10.1016/j.redox.2017.04.033

  • CrossRef
  • Google Scholar

• 70

  GarcíaI. E.SánchezH. A.MartínezA. D.RetamalM. A. (2018). Redox-mediated regulation of connexin proteins; focus on nitric oxide. Biochim. Biophys. Acta Biomembr.1860, 91–95. 10.1016/j.bbamem.2017.10.006

  • CrossRef
  • Google Scholar

• 71

  García-CarmonaJ. A.Martínez-LaordenE.MilanésM. V.LaordenM. L. (2015). Sympathetic activity induced by naloxone-precipitated morphine withdrawal is blocked in genetically engineered mice lacking functional CRF1 receptor. Toxicol. Appl. Pharmacol.283, 42–49. 10.1016/j.taap.2015.01.002

  • CrossRef
  • Google Scholar

• 72

  Garcia-PortillaM. P.Bobes-BascaranM. T.BascaranM. T.SaizP. A.BobesJ. (2014). Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?Br. J. Clin. Pharmacol.77, 272–284. 10.1111/bcp.12031

  • CrossRef
  • Google Scholar

• 73

  GardnerE. L. (2011). Addiction and brain reward and antireward pathways. Adv. Psychosom. Med.30, 22–60. 10.1159/000324065

  • CrossRef
  • Google Scholar

• 74

  GarnerJ. P. (2014). The significance of meaning: why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it?ILAR J.55, 438–456. 10.1093/ilar/ilu047

  • CrossRef
  • Google Scholar

• 75

  GastonB.BabyS. M.MayW. J.YoungA. P.GrossfieldA.BatesJ. N.et al (2021). D-Cystine di(m)ethyl ester reverses the deleterious effects of morphine on ventilation and arterial blood gas chemistry while promoting antinociception. Sci. Rep.11, 10038. 10.1038/s41598-021-89455-2

  • CrossRef
  • Google Scholar

• 76

  GastonB.MayW. J.SullivanS.YemenS.MarozkinaN. V.PalmerL. A.et al (2014). Essential role of hemoglobin beta-93-cysteine in post-hypoxia facilitation of breathing in conscious mice. J. Appl. Physiol.116, 1290–1299. 10.1152/japplphysiol.01050.2013

  • CrossRef
  • Google Scholar

• 77

  GastonB.SingelD.DoctorA.StamlerJ. S. (2006). S-nitrosothiol signaling in respiratory biology. Am. J. Respir. Crit. Care Med.173, 1186–1193. 10.1164/rccm.200510-1584PP

  • CrossRef
  • Google Scholar

• 78

  GastonB.SmithL.BoschJ.SecklerJ.KunzeD.KiselarJ.et al (2020). Voltage-gated potassium channel proteins and stereoselective S-nitroso-l-cysteine signaling. JCI Insight5, e134174. 10.1172/jci.insight.134174

  • CrossRef
  • Google Scholar

• 79

  GetsyP. M.BabyS. M.GruberR. B.GastonB.LewisT. H. J.GrossfieldA.et al (2022c). S-Nitroso-L-Cysteine stereoselectively blunts the deleterious effects of fentanyl on breathing while augmenting antinociception in freely-moving rats. Front. Pharmacol.13, 892307. 10.3389/fphar.2022.892307

  • CrossRef
  • Google Scholar

• 80

  GetsyP. M.BabyS. M.MayW. J.BatesJ. N.EllisC. R.FeaselM. G.et al (2022a). L-cysteine methyl ester overcomes the deleterious effects of morphine on ventilatory parameters and arterial blood-gas chemistry in unanesthetized rats. Front. Pharmacol.13, 968378. 10.3389/fphar.2022.968378

  • CrossRef
  • Google Scholar

• 81

  GetsyP. M.BabyS. M.MayW. J.LewisT. H. J.BatesJ. N.HsiehY. H.et al (2022b). L-NAC reverses of the adverse effects of fentanyl infusion on ventilation and blood-gas chemistry. Biomed. Pharmacother.153, 113277. 10.1016/j.biopha.2022.113277

  • CrossRef
  • Google Scholar

• 82

  GetsyP. M.BabyS. M.MayW. J.YoungA. P.GastonB.HodgesM. R.et al (2022e). D-cysteine ethyl ester reverses the deleterious effects of morphine on breathing and arterial blood-gas chemistry in freely-moving rats. Front. Pharmacol.13, 883329. 10.3389/fphar.2022.883329

  • CrossRef
  • Google Scholar

• 83

  GetsyP. M.CoffeeG. A.LewisS. J. (2023b). Loss of ganglioglomerular nerve input to the carotid body impacts the hypoxic ventilatory response in freely-moving rats. Front. Physiol.14, 1007043. 10.3389/fphys.2023.1007043

  • CrossRef
  • Google Scholar

• 84

  GetsyP. M.DavisJ.CoffeeG. A.LewisT. H. J.LewisS. J. (2023a). Hypercapnic signaling influences hypoxic signaling in the control of breathing in C57BL6 mice. J. Appl. Physiol.134, 1188–1206. 10.1152/japplphysiol.00548.2022

  • CrossRef
  • Google Scholar

• 85

  GetsyP. M.YoungA. P.BatesJ. N.BabyS. M.SecklerJ. M.GrossfieldA.et al (2022f). S-nitroso-L-cysteine stereoselectively blunts the adverse effects of morphine on breathing and arterial blood gas chemistry while promoting analgesia. Biomed. Pharmacother.153, 113436. 10.1016/j.biopha.2022.113436

  • CrossRef
  • Google Scholar

• 86

  GetsyP. M.YoungA. P.GrossfieldA.SecklerJ. M.WilsonC. G.GastonB.et al (2022d). D-cysteine ethyl ester and D-cystine dimethyl ester reverse the deleterious effects of morphine on arterial blood-gas chemistry and Alveolar-arterial gradient in anesthetized rats. Respir Physiol Neurobiol302, 103912. 10.1016/j.resp.2022.103912

  • CrossRef
  • Google Scholar

• 87

  GhezziP.ChanP. (2017). Redox proteomics applied to the thiol secretome. Antioxid. Redox Signal26, 299–312. 10.1089/ars.2016.6732

  • CrossRef
  • Google Scholar

• 88

  GiletaA. F.FitzpatrickC. J.ChitreA. S.St PierreC. L.JoyceE. V.MaguireR. J.et al (2022). Genetic characterization of outbred Sprague Dawley rats and utility for genome-wide association studies. PLoS Genet.18, e1010234. 10.1371/journal.pgen.1010234

  • CrossRef
  • Google Scholar

• 89

  GiustariniD.MilzaniA.Dalle-DonneI.TsikasD.RossiR. (2012). N-Acetylcysteine ethyl ester (NACET): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochem. Pharmacol.84, 1522–1533. 10.1016/j.bcp.2012.09.010

  • CrossRef
  • Google Scholar

• 90

  GlassM. J. (2010). The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence. Vitam. Horm.82, 145–166. 10.1016/S0083-6729(10)82008-4

  • CrossRef
  • Google Scholar

• 91

  GlassM. J. (2011). Opioid dependence and NMDA receptors. ILAR J.52, 342–351. 10.1093/ilar.52.3.342

  • CrossRef
  • Google Scholar

• 92

  GledhillL. J.BabeyA. M. (2021). Synthesis of the mechanisms of opioid tolerance: do we still say NO?Cell Mol. Neurobiol.41, 927–948. 10.1007/s10571-021-01065-8

  • CrossRef
  • Google Scholar

• 93

  GotoK.HisadomeM.KawazoeY.TsumagariT. (1983). Effect of cysteine ethylester hydrochloride (Cystanin) on host defense mechanism]. Nihon Yakurigaku Zasshi82, 27–35. 10.1254/fpj.82.27

  • CrossRef
  • Google Scholar

• 94

  GrimT. W.Acevedo-CanabalA.BohnL. M. (2020). Toward directing opioid receptor signaling to refine opioid therapeutics. Biol. Psychiatry87, 15–21. 10.1016/j.biopsych.2019.10.020

  • CrossRef
  • Google Scholar

• 95

  GutowiczM.KaźmierczakB.Barańczyk-KuźmaA. (2011). The influence of heroin abuse on glutathione-dependent enzymes in human brain. Drug Alcohol Depend.113, 8–12. 10.1016/j.drugalcdep.2010.06.020

  • CrossRef
  • Google Scholar

• 96

  HahJ. M.BatemanB. T.RatliffJ.CurtinC.SunE. (2017). Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth. Analg.125, 1733–1740. 10.1213/ANE.0000000000002458

  • CrossRef
  • Google Scholar

• 97

  HeberleinA.LeggioL.StichtenothD.HillemacherT. (2012). The treatment of alcohol and opioid dependence in pregnant women. Curr. Opin. Psychiatry25, 559–564. 10.1097/YCO.0b013e328358ad36

  • CrossRef
  • Google Scholar

• 98

  HendrieC. A. (1985). Opiate dependence and withdrawal--a new synthesis?Pharmacol. Biochem. Behav.23, 863–870. 10.1016/0091-3057(85)90084-x

  • CrossRef
  • Google Scholar

• 99

  HermanB. H.VocciF.BridgeP. (1995). The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology13, 269–293. 10.1016/0893-133X(95)00140-9

  • CrossRef
  • Google Scholar

• 100

  HessD. T.StamlerJ. S. (2012). Regulation by S-nitrosylation of protein post-translational modification. J. Biol. Chem.287, 4411–4418. 10.1074/jbc.R111.285742

  • CrossRef
  • Google Scholar

• 101

  HisadomeM.FukudaT.TerasawaM. (1990). Effect of cysteine ethylester hydrochloride (Cystanin) on host defense mechanisms (V): potentiation of nitroblue tetrazolium reduction and chemiluminescence in macrophages or leukocytes of mice or rats. Jpn. J. Pharmacol.53, 57–66. 10.1254/jjp.53.57

  • CrossRef
  • Google Scholar

• 102

  HisadomeM.KimuraY.IkegamiK.TerasawaM. (1988). Effect of cysteine ethylester hydrochloride (Cystanin) on host defense mechanism (IV): potentiating effects on the function of peritoneal or spleen macrophages. Jpn. J. Pharmacol.47, 379–385. 10.1254/jjp.47.379

  • CrossRef
  • Google Scholar

• 103

  HisadomeM.NakamuraY.OkumotoT.IkegamiK. (1986a). Effect of cysteine ethylester hydrochloride (Cystanin) on host defense mechanisms (II): restorative effects on the suppression of antibody production. Nihon Yakurigaku Zasshi88, 349–354. 10.1254/fpj.88.349

  • CrossRef
  • Google Scholar

• 104

  HisadomeM.NakamuraY.OkumotoT.IkegamiK. (1986b). Effect of cysteine ethylester hydrochloride (Cystanin) on host defense mechanisms (III): potentiating effects on phagocytosis and nitroblue tetrazolium (NBT) reduction by leukocytes of mice and Guinea pigs. Nihon Yakurigaku Zasshi88, 369–374. 10.1254/fpj.88.369

  • CrossRef
  • Google Scholar

• 105

  HobbsM. J.ButterworthM.CohenG. M.UpshallD. G. (1993). Structure-activity relationships of cysteine esters and their effects on thiol levels in rat lung in vitro. Biochem. Pharmacol.45, 1605–1612. 10.1016/0006-2952(93)90301-c

  • CrossRef
  • Google Scholar

• 106

  HollandL. N.ShusterL. C.BuccafuscoJ. J. (1993). Role of spinal and supraspinal muscarinic receptors in the expression of morphine withdrawal symptoms in the rat. Neuropharmacology32, 1387–1395. 10.1016/0028-3908(93)90035-2

  • CrossRef
  • Google Scholar

• 107

  HornD. B.VuL.PorterB. R.SarantopoulosK. (2023). “Responsible controlled substance and opioid prescribing,” in StatPearls (Treasure Island (FL): StatPearls Publishing). PMID: 34283451.

  • Google Scholar

• 108

  HorsfallJ. T.SpragueJ. E. (2017). The pharmacology and toxicology of the 'holy trinity. Basic Clin. Pharmacol. Toxicol.120, 115–119. 10.1111/bcpt.12655

  • CrossRef
  • Google Scholar

• 109

  HosseiniM.TaiaraniZ.HadjzadehM. A.SalehabadiS.TehranipourM.AlaeiH. A. (2011). Different responses of nitric oxide synthase inhibition on morphine-induced antinociception in male and female rats. Pathophysiology18, 143–149. 10.1016/j.pathophys.2010.05.004

  • CrossRef
  • Google Scholar

• 110

  HoushmandG.PourasgharM.ShiranM.Arab FirozjaeA.GoudarziM.ManouchehrF.et al (2021). Simvastatin prevents morphine antinociceptive tolerance and withdrawal symptoms through antioxidative effect and nitric oxide pathway in mice. Behav. Brain Res.402, 113104. 10.1016/j.bbr.2020.113104

  • CrossRef
  • Google Scholar

• 111

  HuX.TianX.GuoX.HeY.ChenH.ZhouJ.et al (2018). AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence. Neuropharmacology137, 50–58. 10.1016/j.neuropharm.2018.04.020

  • CrossRef
  • Google Scholar

• 112

  HuhnA. S.BerryM. S.DunnK. E. (2019). Review: sex-based differences in treatment outcomes for persons with opioid use disorder. Am. J. Addict.28, 246–261. 10.1111/ajad.12921

  • CrossRef
  • Google Scholar

• 113

  HumphreysK.ShoverC. L.AndrewsC. M.BohnertA. S. B.BrandeauM. L.CaulkinsJ. P.et al (2022). Responding to the opioid crisis in north America and beyond: recommendations of the stanford-lancet commission. Lancet399, 555–604. 10.1016/S0140-6736(21)02252-2

  • CrossRef
  • Google Scholar

• 114

  HutchinsonM. R.BlandS. T.JohnsonK. W.RiceK. C.MaierS. F.WatkinsL. R. (2007). Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal7, 98–111. 10.1100/tsw.2007.230

  • CrossRef
  • Google Scholar

• 115

  IkemotoM. J.InoueK.AkidukiS.OsugiT.ImamuraT.IshidaN.et al (2002). Identification of addicsin/GTRAP3-18 as a chronic morphine-augmented gene in amygdala. Neuroreport13, 2079–2084. 10.1097/00001756-200211150-00018

  • CrossRef
  • Google Scholar

• 116

  IsoardiK. Z.ParkerL.HarrisK.RashfordS.IsbisterG. K. (2022). Acute opioid withdrawal following intramuscular administration of naloxone 1.6 mg: a prospective out-of-hospital series. Ann. Emerg. Med.80, 120–126. 10.1016/j.annemergmed.2022.03.004

  • CrossRef
  • Google Scholar

• 117

  JarrottB.LewisS. J.DoyleA. E.LouisW. J. (1988). Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am. J. Cardiol.61, 39D-44D–44D. 10.1016/0002-9149(88)90463-8

  • CrossRef
  • Google Scholar

• 118

  JarrottB.LewisS. J.LouisW. J.MaccarroneC.ShulkesA. (1987). Regional brain concentrations of several putative peptide neurotransmitters in normotensive and spontaneously hypertensive rats: effects of continuous (10-day) clonidine infusion. J. Cardiovasc Pharmacol.10, S14–S21. Suppl 12. 10.1097/00005344-198709002-00002

  • CrossRef
  • Google Scholar

• 119

  JenkinsM. W.KhalidF.BabyS. M.MayW. J.YoungA. P.BatesJ. N.et al (2021). Glutathione ethyl ester reverses the deleterious effects of fentanyl on ventilation and arterial blood-gas chemistry while prolonging fentanyl-induced analgesia. Sci. Rep.11, 6985. 10.1038/s41598-021-86458-x

  • CrossRef
  • Google Scholar

• 120

  Jiménez-FernándezB.Calomarde-GómezC.López-LazcanoA.LligoñaA.GualA.López-PelayoH. (2022). Systematic review on the clinical management of chronic pain and comorbid opioid use disorder. Adicciones0, 1680. 10.20882/adicciones.1680

  • CrossRef
  • Google Scholar

• 121

  JosephC. A.MaroneyM. J. (2007). Cysteine dioxygenase: structure and mechanism. Chem. Commun. (Camb).32, 3338–3349. 10.1039/b702158e

  • CrossRef
  • Google Scholar

• 122

  KanbarR.StornettaR. L.CashD. R.LewisS. J.GuyenetP. G. (2010). Photostimulation of Phox2b medullary neurons activates cardiorespiratory function in conscious rats. Am. J. Respir. Crit. Care Med.182, 1184–1194. 10.1164/rccm.201001-0047OC

  • CrossRef
  • Google Scholar

• 123

  KestB.PalmeseC. A.JuniA.CheslerE. J.MogilJ. S. (2004). Mapping of a quantitative trait locus for morphine withdrawal severity. Mamm. Genome15, 610–617. 10.1007/s00335-004-2367-3

  • CrossRef
  • Google Scholar

• 124

  KimuraH. (2014). The physiological role of hydrogen sulfide and beyond. Nitric Oxide41, 4–10. 10.1016/j.niox.2014.01.002

  • CrossRef
  • Google Scholar

• 125

  KimuraH. (2017). Hydrogen sulfide and polysulfide signaling. Antioxid. Redox Signal.27, 619–621. 10.1089/ars.2017.7076

  • CrossRef
  • Google Scholar

• 126

  KnaussZ. T.HearnC. J.HendryxN. C.AboalrobF. S.Mueller-FigueroaY.DamronD. S.et al (2023). Fentanyl-induced reward seeking is sex and dose dependent and is prevented by D-cysteine ethylester. Front. Pharmacol.14, 1241578. 10.3389/fphar.2023.1241578

  • CrossRef
  • Google Scholar

• 127

  KnouseM. C.BriandL. A. (2021). Behavioral sex differences in cocaine and opioid use disorders: the role of gonadal hormones. Neurosci. Biobehav Rev.128, 358–366. 10.1016/j.neubiorev.2021.06.038

  • CrossRef
  • Google Scholar

• 128

  KoobG. F. (1987). Neural substrates of opioid tolerance and dependence. NIDA Res. Monogr.76, 46–52.

  • Google Scholar

• 129

  KoobG. F. (2020). Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol. Psychiatry87, 44–53. 10.1016/j.biopsych.2019.05.023

  • CrossRef
  • Google Scholar

• 130

  KoobG. F.VolkowN. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry3, 760–773. 10.1016/S2215-0366(16)00104-8

  • CrossRef
  • Google Scholar

• 131

  KregelK. C.KenneyM. J.MassettM. P.MorganD. A.LewisS. J. (1997). Role of nitrosyl factors in the hemodynamic adjustments to heat stress in the rat. Am. J. Physiol.273, H1537–H1543. 10.1152/ajpheart.1997.273.3.H1537

  • CrossRef
  • Google Scholar

• 132

  KularatneR. N.BulumullaC.CatchpoleT.TakacsA.ChristieA.StefanM. C.et al (2020). Protection of human retinal pigment epithelial cells from oxidative damage using cysteine prodrugs. Free Radic. Biol. Med.152, 386–394. 10.1016/j.freeradbiomed.2020.03.024

  • CrossRef
  • Google Scholar

• 133

  LaschkaE.HerzA. (1977). Sites of action of morphine involved in the development of physical dependence in rats. III. Autoradiographic studies. III. Autoradiogr. Stud. Psychopharmacol. Berl.53, 33–37. 10.1007/BF00426691

  • CrossRef
  • Google Scholar

• 134

  LaschkaE.HerzA.BläsigJ. (1976a). Sites of action of morphine involved in the development of physical dependence in rats. I. Comparison of precipitated morphine withdrawal after intraperitoneal and intraventricular injection of morphine antagonists. Psychopharmacologia46, 133–139. 10.1007/BF00421382

  • CrossRef
  • Google Scholar

• 135

  LaschkaE.TeschemacherH.MehraeinP.HerzA. (1976b). Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia46, 141–147. 10.1007/BF00421383

  • CrossRef
  • Google Scholar

• 136

  LashL. H.JonesD. P. (1985). Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma. Arch. Biochem. Biophys.240, 583–592. 10.1016/0003-9861(85)90065-7

  • CrossRef
  • Google Scholar

• 137

  LaskaF. J.FennessyM. R. (1977). Dissociation of increased 5-hydroxyindoleacetic acid levels and physical dependence: the effects of naloxone. Clin. Exp. Pharmacol. Physiol.4, 515–523. 10.1111/j.1440-1681.1977.tb02681.x

  • CrossRef
  • Google Scholar

• 138

  LaskaF. J.FennessyM. R. (1978). Induction of physical dependence on cyclazocine and pentazocine in the rat. Eur. J. Pharmacol.48, 57–65. 10.1016/0014-2999(78)90044-4

  • CrossRef
  • Google Scholar

• 139

  LaskaJ. F.FennessyM. R. (1976). Physical dependence in the rat induced by slow release morphine: dose-response, time course and brain biogenic amines. Clin. Exp. Pharmacol. Physiol.3, 587–598. 10.1111/j.1440-1681.1976.tb00640.x

  • CrossRef
  • Google Scholar

• 140

  LeeJ. R.FennessyM. R. (1970). The relationship between morphine analgesia and the levels of biogenic amines in the mouse brain. Eur. J. Pharmacol.12, 65–70. 10.1016/0014-2999(70)90029-4

  • CrossRef
  • Google Scholar

• 141

  LeeS.TatlaV.BugaS.PonD. (2022). Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients. J. Opioid Manag.18, 497–502. 10.5055/jom.2022.0744

  • CrossRef
  • Google Scholar

• 142

  LevinC. J.WaiJ. M.JonesJ. D.ComerS. D. (2019). Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal. Drug Alcohol Depend.204, 107538. 10.1016/j.drugalcdep.2019.06.040

  • CrossRef
  • Google Scholar

• 143

  LewisS. J.DunlopM.JarrottB. (1989). Serum glucose and insulin levels in normotensive (WKY) and spontaneously hypertensive (SH) rats during and after the cessation of continuous (10 day) clonidine infusion. J. Pharm. Pharmacol.41, 353–355. 10.1111/j.2042-7158.1989.tb06474.x

  • CrossRef
  • Google Scholar

• 144

  LewisS. J.HoqueA.BatesJ. N. (2005). Differentiation of L- and D-S-nitrosothiol recognition sites in vivo. J. Cardiovasc Pharmacol.46, 660–671. 10.1097/01.fjc.0000181714.94827.5d

  • CrossRef
  • Google Scholar

• 145

  LewisS. J.OwenJ. R.BatesJ. N. (2006). S-nitrosocysteine elicits hemodynamic responses similar to those of the Bezold-Jarisch reflex via activation of stereoselective recognition sites. Eur. J. Pharmacol.531, 254–258. 10.1016/j.ejphar.2005.11.027

  • CrossRef
  • Google Scholar

• 146

  LewisS. J.RoweP.JarrottB. (1988a). Involvement of hypothalamic adrenaline in the clonidine withdrawal syndrome in normotensive and spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol.15, 773–780. 10.1111/j.1440-1681.1988.tb01017.x

  • CrossRef
  • Google Scholar

• 147

  LewisS. J.SvecJ.FennessyM. R.JarrottB. (1988b). Lack of involvement of endogenous mu-receptor opioids in the hypothermic effects of clonidine in normotensive and spontaneously hypertensive rats. Neuropharmacology27, 537–540. 10.1016/0028-3908(88)90137-2

  • CrossRef
  • Google Scholar

• 148

  LewisS. J.TravisM. D.BatesJ. N. (1996). Stereoselective S-nitrosocysteine recognition sites in rat brain. Eur. J. Pharmacol.312, R3–R5. 10.1016/0014-2999(96)00607-3

  • CrossRef
  • Google Scholar

• 149

  LewisT. H. J.MayW. J.YoungA. P.BatesJ. N.BabyS. M.GetsyP. M.et al (2022). The ventilatory depressant actions but not the antinociceptive effects of morphine are blunted in rats receiving intravenous infusion of L-cysteine ethyl ester. Biomed. Pharmacother.156, 113939. 10.1016/j.biopha.2022.113939

  • CrossRef
  • Google Scholar

• 150

  LezaJ. C.LizasoainI.CuéllarB.MoroM. A.LorenzoP. (1996). Correlation between brain nitric oxide synthase activity and opiate withdrawal. Naunyn Schmiedeb. Arch. Pharmacol.353, 349–354. 10.1007/BF00168639

  • CrossRef
  • Google Scholar

• 151

  LezaJ. C.LizasoainI.San-Martín-ClarkO.LorenzoP. (1995). Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity. Eur. J. Pharmacol.285, 95–98. 10.1016/0014-2999(95)00474-y

  • CrossRef
  • Google Scholar

• 152

  LiF.JiangH.ShenX.YangW.GuoC.WangZ.et al (2021). Sneezing reflex is mediated by a peptidergic pathway from nose to brainstem. Cell184, 3762–3773.e10. 10.1016/j.cell.2021.05.017

  • CrossRef
  • Google Scholar

• 153

  LiY.SuL.LiF.WangC.YuanD.ChenJ.et al (2015). Acute and sub-chronic toxicity of glucose-cysteine Maillard reaction products in Sprague-Dawley rats. Food Chem. Toxicol.80, 271–276. 10.1016/j.fct.2015.03.021

  • CrossRef
  • Google Scholar

• 154

  LiangD. Y.ShiX.LiX.LiJ.ClarkJ. D. (2007). The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav. Brain Res.181, 118–126. 10.1016/j.bbr.2007.03.037

  • CrossRef
  • Google Scholar

• 155

  LimG.WangS.MaoJ. (2012). cAMP and protein kinase A contribute to the downregulation of spinal glutamate transporters after chronic morphine. Neurosci. Lett.376, 9–13. 10.1016/j.neulet.2004.11.016

  • CrossRef
  • Google Scholar

• 156

  LinC. I.OrlovI.RuggieroA. M.Dykes-HobergM.LeeA.JacksonM.et al (2001). Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature410, 84–88. 10.1038/35065084

  • CrossRef
  • Google Scholar

• 157

  LiptonA. J.JohnsonA.MacdonaldT.LiebermanM. W.GozalD.GastonB. (2001). S-nitrosothiols signal the ventilatory response to hypoxia. Nature413, 171–174. 10.1038/35093117

  • CrossRef
  • Google Scholar

• 158

  LiptonS. A.ChoiY. B.PanZ. H.LeiS. Z.ChenH. S.SucherN. J.et al (1993). A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature364, 626–632. 10.1038/364626a0

  • CrossRef
  • Google Scholar

• 159

  LiuL.FuY.HeH.JiF.LiuF.CaoM. (2011). Expression of EAAT3 in prefrontal cortex and hippocampus in CPP reinstatement rats induced by morphine. Chin. J. Pathophysiol.27, 1720–1724.

  • Google Scholar

• 160

  LiuZ.ZhengJ. F.YangL. Q.YiL.HuB. (2007). Effects of sinomenine on NO/nNOS system in cerebellum and spinal cord of morphine-dependent and withdrawal mice. Sheng Li Xue Bao59, 285–292.

  • Google Scholar

• 161

  LofwallM. R.BabalonisS.NuzzoP. A.SiegelA.CampbellC.WalshS. L. (2013). Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend.133, 188–197. 10.1016/j.drugalcdep.2013.05.010

  • CrossRef
  • Google Scholar

• 162

  LondonE. D.KimesA. S.VaupelD. B. (1995). Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. NIDA Res. Monogr.147, 170–181.

  • Google Scholar

• 163

  Lopez-GimenezJ. F.MilliganG. (2010). Opioid regulation of mu receptor internalisation: relevance to the development of tolerance and dependence. CNS Neurol. Disord. Drug Targets9, 616–626. 10.2174/187152710793361522

  • CrossRef
  • Google Scholar

• 164

  LudbrookJ. (1998). Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol.25, 1032–1037. 10.1111/j.1440-1681.1998.tb02179.x

  • CrossRef
  • Google Scholar

• 165

  MajeedN. H.PrzewłockaB.MachelskaH.PrzewłockiR. (1994). Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology33, 189–192. 10.1016/0028-3908(94)90006-x

  • CrossRef
  • Google Scholar

• 166

  ManhapraA. (2022). Complex persistent opioid dependence-an opioid-induced chronic pain syndrome. Curr. Treat. Options Oncol.23, 921–935. 10.1007/s11864-022-00985-x

  • CrossRef
  • Google Scholar

• 167

  MansouriM. T.NaghizadehB.GhorbanzadehB.AmirgholamiN.HoushmandG.AlboghobeishS. (2020). Venlafaxine inhibits naloxone-precipitated morphine withdrawal symptoms: role of inflammatory cytokines and nitric oxide. Metab. Brain Dis.35, 305–313. 10.1007/s11011-019-00491-4

  • CrossRef
  • Google Scholar

• 168

  MaoJ.SungB.JiR.-R.LimG. (2002). Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J. Neurosci.22, 8312–8323. 10.1523/JNEUROSCI.22-18-08312.2002

  • CrossRef
  • Google Scholar

• 169

  MarshallD. C.BuccafuscoJ. J. (1985). Supraspinal and spinal mediation of naloxone-induced morphine withdrawal in rats. Brain Res.329, 131–142. 10.1016/0006-8993(85)90518-9

  • CrossRef
  • Google Scholar

• 170

  MarshallD. C.BuccafuscoJ. J. (1987). Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. J. Neurosci.7, 621–628. 10.1523/JNEUROSCI.07-03-00621.1987

  • CrossRef
  • Google Scholar

• 171

  MatsonP. A.RidenourT.IalongoN.SpothR.PradoG.HammondC. J.et al (2022). State of the art in substance use prevention and early intervention: applications to pediatric primary care settings. Prev. Sci.23, 204–211. 10.1007/s11121-021-01299-4

  • CrossRef
  • Google Scholar

• 172

  MazeI.NestlerE. J. (2011). The epigenetic landscape of addiction. Ann. N. Y. Acad. Sci.1216, 99–113. 10.1111/j.1749-6632.2010.05893.x

  • CrossRef
  • Google Scholar

• 173

  McCarbergB. H. (2011). Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad. Med.123, 119–130. 10.3810/pgm.2011.03.2270

  • CrossRef
  • Google Scholar

• 174

  McHughM. L. (2011). Multiple comparison analysis testing in ANOVA. Biochem. Med. Zagreb.21, 203–209. 10.11613/bm.2011.029

  • CrossRef
  • Google Scholar

• 175

  MendozaJ.PassafaroR.BabyS.YoungA. P.BatesJ. N.GastonB.et al (2013). L-Cysteine ethyl ester reverses the deleterious effects of morphine on, arterial blood-gas chemistry in tracheotomized rats. Respir. Physiol. Neurobiol.189, 136–143. 10.1016/j.resp.2013.07.007

  • CrossRef
  • Google Scholar

• 176

  MercadanteS.ArcuriE.SantoniA. (2019). Opioid-induced tolerance and hyperalgesia. CNS Drugs33, 943–955. 10.1007/s40263-019-00660-0

  • CrossRef
  • Google Scholar

• 177

  MichaudN.CoutureR. (2003). Cardiovascular and behavioural effects induced by naloxone-precipitated morphine withdrawal in rat: characterization with tachykinin antagonists. Neuropeptides37, 345–354. 10.1016/j.npep.2003.09.003

  • CrossRef
  • Google Scholar

• 178

  MorganM. M.ChristieM. J. (2011). Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br. J. Pharmacol.164, 1322–1334. 10.1111/j.1476-5381.2011.01335.x

  • CrossRef
  • Google Scholar

• 179

  MoriT.ItoS.MatsubayashiK.SawaguchiT. (2007). Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome. Behav. Pharmacol.18, 725–729. 10.1097/FBP.0b013e3282f18da6

  • CrossRef
  • Google Scholar

• 180

  Mosier-BossP. A.LiebermanS. H. (2005). The role of hydrogen bonding in the selectivity of L-cysteine methyl ester (CYSM) and L-cysteine ethyl ester (CYSE) for chloride ion. Spectrochim. Acta A Mol. Biomol. Spectrosc.61, 845–854. 10.1016/j.saa.2004.06.011

  • CrossRef
  • Google Scholar

• 181

  MyersP. R.MinorR. L.JrGuerraR.JrBatesJ. N.HarrisonD. G. (1990). Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature345, 161–163. 10.1038/345161a0

  • CrossRef
  • Google Scholar

• 182

  NaiduP. S.SinghA.JoshiD.KulkarniS. K. (2003). Possible mechanisms of action in quercetin reversal of morphine tolerance and dependence. Addict. Biol.8, 327–336. 10.1080/13556210310001602248

  • CrossRef
  • Google Scholar

• 183

  NewlinD. B.WongC. J.CheskinL. J. (1992). Cardiovascular responses to naloxone challenge in opiate-dependent individuals. Pharmacol. Biochem. Behav.43, 357–360. 10.1016/0091-3057(92)90162-9

  • CrossRef
  • Google Scholar

• 184

  NielsenD. A.KreekM. J. (2012). Common and specific liability to addiction: approaches to association studies of opioid addiction. Drug Alcohol Depend.123, S33–S41. 10.1016/j.drugalcdep.2012.03.026

  • CrossRef
  • Google Scholar

• 185

  NishidaK.OhtaY.ItoM.NagamuraY.KitaharaS.FujiiK.et al (1996). Conversion of gamma-glutamylcysteinylethyl ester to glutathione in rat hepatocytes. Biochim. Biophys. Acta1313, 47–53. 10.1016/0167-4889(96)00054-7

  • CrossRef
  • Google Scholar

• 186

  NodaY.NabeshimaT. (2004). Opiate physical dependence and N-methyl-D-aspartate receptors. Eur. J. Pharmacol.500, 121–128. 10.1016/j.ejphar.2004.07.017

  • CrossRef
  • Google Scholar

• 187

  OhtaH.BatesJ. N.LewisS. J.TalmanW. T. (1997). Actions of S-nitrosocysteine in the nucleus tractus solitarii are unrelated to release of nitric oxide. Brain Res.746, 98–104. 10.1016/s0006-8993(96)01188-2

  • CrossRef
  • Google Scholar

• 188

  OstreaE. M.JrChavezC. J.StraussM. E. (1975). A study of factors that influence the severity of neonatal narcotic withdrawal. Addict. Dis.2, 187–199.

  • Google Scholar

• 189

  O-UchiJ.RyuS. Y.JhunB. S.HurstS.SheuS. S. (2014). Mitochondrial ion channels/transporters as sensors and regulators of cellular redox signaling. Antioxid. Redox Signal21, 987–1006. 10.1089/ars.2013.5681

  • CrossRef
  • Google Scholar

• 190

  Owusu ObengA.HamadehI.SmithM. (2017). Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy37, 1105–1121. 10.1002/phar.1986

  • CrossRef
  • Google Scholar

• 191

  PalmerL. A.deRondeK.Brown-SteinkeK.GunterS.JyothikumarV.ForbesM. S.et al (2015). Hypoxia-induced changes in protein S-nitrosylation in female mouse brainstem. Am. J. Respir. Cell Mol. Biol.52, 37–45. 10.1165/rcmb.2013-0359OC

  • CrossRef
  • Google Scholar

• 192

  PalmerL. A.MayW. J.deRondeK.Brown-SteinkeK.BatesJ. N.GastonB.et al (2013). Ventilatory responses during and following exposure to a hypoxic challenge in conscious mice deficient or null in S-nitrosoglutathione reductase. Resp. Physiol. Neurobiol.185, 571–581. 10.1016/j.resp.2012.11.009

  • CrossRef
  • Google Scholar

• 193

  PerissinottiL. L.TurjanskiA. G.EstrinD. A.DoctorovichF. (2005). Transnitrosation of nitrosothiols: characterization of an elusive intermediate. J. Am. Chem. Soc.127, 486–487. 10.1021/ja044056v

  • CrossRef
  • Google Scholar

• 194

  PhilipV. M.DuvvuruS.GomeroB.AnsahT. A.BlahaC. D.CookM. N.et al (2010). High-throughput behavioral phenotyping in the expanded panel of BXD recombinant inbred strains. Genes Brain Behav.9, 129–159. 10.1111/j.1601-183X.2009.00540.x

  • CrossRef
  • Google Scholar

• 195

  PrabhakarN. R. (2012). Hydrogen sulfide (H(2)S): a physiologic mediator of carotid body response to hypoxia. Adv. Exp. Med. Biol.758, 109–113. 10.1007/978-94-007-4584-1_15

  • CrossRef
  • Google Scholar

• 196

  PreuxC.BertinM.TarotA.AuthierN.PinolN.BrugnonD.et al (2022). Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review. J. Clin. Med.11, 1594. 10.3390/jcm11061594

  • CrossRef
  • Google Scholar

• 197

  PurssellR.GodwinJ.MoeJ.BuxtonJ.CrabtreeA.KestlerA.et al (1995). Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology13, 315–322. 10.1016/0893-133X(95)00138-4

  • CrossRef
  • Google Scholar

• 198

  RaghavendraV.KulkarniS. K. (1999). Reversal of morphine tolerance and dependence by melatonin: possible role of central and peripheral benzodiazepine receptors. Brain Res.834, 178–181. 10.1016/s0006-8993(99)01520-6

  • CrossRef
  • Google Scholar

• 199

  RaghavendraV.KulkarniS. K. (2000). Possible mechanisms of action in melatonin reversal of morphine tolerance and dependence in mice. Eur. J. Pharmacol.409, 279–289. 10.1016/s0014-2999(00)00849-9

  • CrossRef
  • Google Scholar

• 200

  RamirezJ. M.VlemincxE.BaertschN. A.SeversL. J. (2022). The sigh and related behaviors. Handb. Clin. Neurol.188, 357–372. 10.1016/B978-0-323-91534-2.00015-1

  • CrossRef
  • Google Scholar

• 201

  RasmussenK. (1995). The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Neuropsychopharmacology13, 295–300. 10.1016/0893-133X(95)00082-O

  • CrossRef
  • Google Scholar

• 202

  RossiR.GiustariniD.MilzaniA.Dalle-DonneI. (2009). Cysteinylation and homocysteinylation of plasma protein thiols during ageing of healthy human beings. J. Cell Mol. Med.13, 3131–3140. 10.1111/j.1582-4934.2008.00417.x

  • CrossRef
  • Google Scholar

• 203

  SacknerM. A.LopezJ. R.BanderasV.AdamsJ. A. (2019). Holistic approach to opioid use disorder: think nitric oxide. J. Opioid Manag.15, 521–555. 10.5055/jom.2019.0543

  • CrossRef
  • Google Scholar

• 204

  SaiepourM. H.SemnanianS.FathollahiY. (2001). Occurrence of morphine tolerance and dependence in the nucleus paragigantocellularis neurons. Eur. J. Pharmacol.411, 85–92. 10.1016/s0014-2999(00)00862-1

  • CrossRef
  • Google Scholar

• 205

  SaklothF.PolizuC.BertheratF.ZachariouV. (2020). Regulators of G Protein signaling in analgesia and addiction. Mol. Pharmacol.98, 739–750. 10.1124/mol.119.119206

  • CrossRef
  • Google Scholar

• 206

  SartonE.DahanA.TeppemaL. (1998). Do sex-related differences exist in the respiratory pharmacology of opioids?Adv. Exp. Med. Biol.450, 141–145. 10.1007/978-1-4757-9077-1_23

  • CrossRef
  • Google Scholar

• 207

  SaulM. C.PhilipV. M.ReinholdtL. G.Center for Systems Neurogenetics of AddictionCheslerE. J. (2019). High-diversity mouse populations for complex traits. Trends Genet.35, 501–514. 10.1016/j.tig.2019.04.003

  • CrossRef
  • Google Scholar

• 208

  SchmidC. L.KennedyM.RossN. C.LovellK. M.YueZ.MorgenweckJ.et al (2017). Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell171, 1165–1175. 10.1016/j.cell.2017.10.035

  • CrossRef
  • Google Scholar

• 209

  SchöneichC.DillingerU.von BruchhausenF.AsmusK. D. (1992). Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals: reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch. Biochem. Biophys.292, 456–467. 10.1016/0003-9861(92)90016-p

  • CrossRef
  • Google Scholar

• 210

  SchwarzerA.Aichinger-HinterhoferM.MaierC.VollertJ.WaltherJ. W. (2015). Sleep-disordered breathing decreases after opioid withdrawal: results of a prospective controlled trial. Pain156, 2167–2174. 10.1097/j.pain.0000000000000279

  • CrossRef
  • Google Scholar

• 211

  SecklerJ. M.GrossfieldA.MayW. J.GetsyP. M.LewisS. J. (2022). Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats. Biomed. Pharmacother.146, 112571. 10.1016/j.biopha.2021.112571

  • CrossRef
  • Google Scholar

• 212

  SecklerJ. M.MeyerN. M.BurtonS. T.BatesJ. N.GastonB.LewisS. J. (2017). Detection of trace concentrations of S-nitrosothiols by means of a capacitive sensor. PLoS One12, grime0187149. 10.1371/journal.pone.0187149

  • CrossRef
  • Google Scholar

• 213

  SecklerJ. M.ShenJ.LewisT. H. J.AbdulameerM. A.ZamanK.PalmerL. A.et al (2020). NADPH diaphorase detects S-nitrosylated proteins in aldehyde-treated biological tissues. Sci. Rep.10, 21088. 10.1038/s41598-020-78107-6

  • CrossRef
  • Google Scholar

• 214

  SemenzaE. R.HarrazM. M.AbramsonE.MallaA. P.VasavdaC.GadallaM. M.et al (2021). D-cysteine is an endogenous regulator of neural progenitor cell dynamics in the mammalian brain. Proc. Natl. Acad. Sci. U. S. A.118, e2110610118. 10.1073/pnas.2110610118

  • CrossRef
  • Google Scholar

• 215

  SerafiniR. A.ZachariouV. (2019). Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone. J. Clin. Invest.129, 2653–2654. 10.1172/JCI128987

  • CrossRef
  • Google Scholar

• 216

  ServinA. L.GoulinetS.RenaultH. (1988). Pharmacokinetics of cysteine ethyl ester in rat. Xenobiotica18, 839–847. 10.3109/00498258809041722

  • CrossRef
  • Google Scholar

• 217

  SethD.StamlerJ. S. (2011). The SNO-proteome: causation and classifications. Curr. Opin. Chem. Biol.15, 129–136. 10.1016/j.cbpa.2010.10.012

  • CrossRef
  • Google Scholar

• 218

  SinghA.NaiduP. S.KulkarniS. K. (2002). Quercetin, a bioflavonoid reverses development of tolerance and dependence to morphine. Drug Dev. Res.57, 167–172. 10.1002/ddr.10119

  • CrossRef
  • Google Scholar

• 219

  SinghP.SharmaB.GuptaS.SharmaB. M. (2015). In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator. Psychopharmacol. Berl.232, 465–475. 10.1007/s00213-014-3680-5

  • CrossRef
  • Google Scholar

• 220

  SinghV. P.JainN. K.KulkarniS. K. (2003). Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways. Methods Find. Exp. Clin. Pharmacol.25, 273–280. 10.1358/mf.2003.25.4.769675

  • CrossRef
  • Google Scholar

• 221

  SpeckerS.WananukulW.HatsukamiD.NolinK.HookeL.KreekM. J.et al (1998). Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacol. Berl.137, 326–332. 10.1007/s002130050626

  • CrossRef
  • Google Scholar

• 222

  StephanB. C.ParsaF. D. (2016). Avoiding opioids and their harmful side effects in the postoperative patient: exogenous opioids, endogenous endorphins, wellness, mood, and their relation to postoperative pain. Hawaii J. Med. Public Health75, 63–67.

  • Google Scholar

• 223

  StipanukM. H.SimmonsC. R.KarplusP. A.DominyJ. E.Jr (2011). Thiol dioxygenases: unique families of cupin proteins. Amino Acids41, 91–102. 10.1007/s00726-010-0518-2

  • CrossRef
  • Google Scholar

• 224

  StipanukM. H.UekiI.DominyJ. E.JrSimmonsC. R.HirschbergerL. L. (2009). Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids37, 55–63. 10.1007/s00726-008-0202-y

  • CrossRef
  • Google Scholar

• 225

  StomberskiC. T.HessD. T.StamlerJ. S. (2019). Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-Nitrosothiol-Based signaling. Antioxid. Redox Signal30, 1331–1351. 10.1089/ars.2017.7403

  • CrossRef
  • Google Scholar

• 226

  SunH.MazeI.DietzD. M.ScobieK. N.KennedyP. J.Damez-WernoD.et al (2012). Morphine epigenomically regulates behavior through alterations in histone H3 lysine 9 dimethylation in the nucleus accumbens. J. Neurosci.32, 17454–17464. 10.1523/JNEUROSCI.1357-12.2012

  • CrossRef
  • Google Scholar

• 227

  SzwergoldB. S. (2006). Alpha-thiolamines such as cysteine and cysteamine act as effective transglycating agents due to formation of irreversible thiazolidine derivatives. Med. Hypotheses66, 698–707. 10.1016/j.mehy.2005.10.029

  • CrossRef
  • Google Scholar

• 228

  TangL.ShuklaP. K.WangL. X.WangZ. J. (2006). Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca2+/calmodulin-dependent protein kinase II. J. Pharmacol. Exp. Ther.317, 901–909. 10.1124/jpet.105.097733

  • CrossRef
  • Google Scholar

• 229

  TokuyamaS.FengY.WakabayashiH.HoI. K. (1995). Ca2+ channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats. Eur. J. Pharmacol.279, 93–98. 10.1016/0014-2999(95)00140-g

  • CrossRef
  • Google Scholar

• 230

  Torres-LockhartK. E.LuT. Y.WeimerM. B.SteinM. R.CunninghamC. O. (2022). Clinical management of opioid withdrawal. Addiction117, 2540–2550. 10.1111/add.15818

  • CrossRef
  • Google Scholar

• 231

  TosiG. M.GiustariniD.FranciL.MinettiA.ImperatoreF.CaldiE.et al (2021). Superior properties of N-acetylcysteine ethyl ester over N-acetyl cysteine to prevent retinal pigment epithelial cells oxidative damage. Int. J. Mol. Sci.22, 600. 10.3390/ijms22020600

  • CrossRef
  • Google Scholar

• 232

  TravisM. D.DavissonR. L.BatesJ. N.LewisS. J. (1997). Hemodynamic effects of L- and D-S-nitroso-beta,beta-dimethylcysteine in rats. Am. J. Physiol.273, H1493–H1501. 10.1152/ajpheart.1997.273.3.H1493

  • CrossRef
  • Google Scholar

• 233

  TravisM. D.StollL.BatesJ. N.LewisS. J. (1996). L- and D-S-nitroso-beta,beta-dimethylcysteine differentially increase cGMP in cultured vascular smooth muscle cells. Eur. J. Pharmacol.318, 47–53. 10.1016/s0014-2999(96)00719-4

  • CrossRef
  • Google Scholar

• 234

  TrivediM.ShahJ.HodgsonN.ByunH. M.DethR. (2014). Morphine induces redox-based changes in global DNA methylation and retrotransposon transcription by inhibition of excitatory amino acid transporter type 3-mediated cysteine uptake. Mol. Pharmacol.85, 747–757. 10.1124/mol.114.091728

  • CrossRef
  • Google Scholar

• 235

  TrivediM. S.DethR. (2015). Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention. Front. Neurosci.8, 444. 10.3389/fnins.2014.00444

  • CrossRef
  • Google Scholar

• 236

  TrivediM. S.HodgsonN. W.WalkerS. J.TrooskensG.NairV.DethR. C. (2015). Epigenetic effects of casein-derived opioid peptides in SH-SY5Y human neuroblastoma cells. Nutr. Metab. (Lond)12, 54. 10.1186/s12986-015-0050-1

  • CrossRef
  • Google Scholar

• 237

  TsakovaA.SurchevaS.SimeonovaK.AltankovaI.MarinovaT.UsunoffK.et al (2015). Nitroxidergic modulation of behavioural, cardiovascular and immune responses, and brain NADPH diaphorase activity upon morphine tolerance/dependence in rats. Biotechnol. Biotechnol. Equip.29, 92–100. 10.1080/13102818.2014.990924

  • CrossRef
  • Google Scholar

• 238

  TurellL.RadiR.AlvarezB. (2013). The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic. Biol. Med.65, 244–253. 10.1016/j.freeradbiomed.2013.05.050

  • CrossRef
  • Google Scholar

• 239

  UndemB. J.KajekarR.HunterD. D.MyersA. C. (2000). Neural integration and allergic disease. J. Allergy Clin. Immunol.106, S213–S220. 10.1067/mai.2000.110153

  • CrossRef
  • Google Scholar

• 240

  VaupelD. B.KimesA. S.LondonE. D. (1995a). Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology13, 315–322. 10.1016/0893-133X(95)00138-4

  • CrossRef
  • Google Scholar

• 241

  VaupelD. B.KimesA. S.LondonE. D. (1995b). Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacol. Berl.118, 361–368. 10.1007/BF02245935

  • CrossRef
  • Google Scholar

• 242

  VolkowN.BenvenisteH.McLellanA. T. (2018). Use and misuse of opioids in chronic pain. Annu. Rev. Med.69, 451–465. 10.1146/annurev-med-011817-044739

  • CrossRef
  • Google Scholar

• 243

  VolkowN. D.MichaelidesM.BalerR. (2019). The neuroscience of drug reward and addiction. Physiol. Rev.99, 2115–2140. 10.1152/physrev.00014.2018

  • CrossRef
  • Google Scholar

• 244

  WallensteinS.ZuckerC. L.FleissJ. L. (1980). Some statistical methods useful in circulation research. Circ. Res.47, 1–9. 10.1161/01.res.47.1.1

  • CrossRef
  • Google Scholar

• 245

  WalshS. L.StrainE. C.BigelowG. E. (2003). Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction98, 427–439. 10.1046/j.1360-0443.2003.00372.x

  • CrossRef
  • Google Scholar

• 246

  WangD.ChenP.LiQ.QuirionR.HongY. (2011). Blockade of adrenomedullin receptors reverses morphine tolerance and its neurochemical mechanisms. Behav. Brain Res.221, 83–90. 10.1016/j.bbr.2011.02.046

  • CrossRef
  • Google Scholar

• 247

  WangQ.Liu-ChenL.-Y.TraynorJ. R. (2009). Differential modulation of μ- and δ-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells. J. Biol. Chem.284, 18357–18367. 10.1074/jbc.M109.015453

  • CrossRef
  • Google Scholar

• 248

  WangZ.BilskyE. J.WangD.PorrecaF.SadéeW. (1999). 3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. Eur. J. Pharmacol.371, 1–9. 10.1016/s0014-2999(99)00131-4

  • CrossRef
  • Google Scholar

• 249

  WangZ. J.TangL.XinL. (2003). Reversal of morphine antinociceptive tolerance by acute spinal inhibition of Ca2+/calmodulin-dependent protein kinase II. Eur. J. Pharmacol.465, 199–200. 10.1016/s0014-2999(03)01484-5

  • CrossRef
  • Google Scholar

• 250

  WardP.MossH. G.BrownT. R.KalivasP.JenkinsD. D. (2020). N-acetylcysteine mitigates acute opioid withdrawal behaviors and CNS oxidative stress in neonatal rats. Pediatr. Res.88, 77–84. 10.1038/s41390-019-0728-6

  • CrossRef
  • Google Scholar

• 251

  WilckenD. E.GuptaV. J. (1979). Cysteine-homocysteine mixed disulphide: differing plasma concentrations in normal men and women. Clin. Sci. (Lond).57, 211–215. 10.1042/cs0570211

  • CrossRef
  • Google Scholar

• 252

  WilsonM.FritzR.FinlayM.CookD. J. (2023). Piloting smart home sensors to detect overnight respiratory and withdrawal symptoms in adults prescribed opioids. Pain Manag. Nurs.24, 4–11. 10.1016/j.pmn.2022.08.011

  • CrossRef
  • Google Scholar

• 253

  WinerB. J. (1971). Statistical principles of experimental design. McGraw-Hill Book Co., 752–809.

  • Google Scholar

• 254

  WinklerA.KutchanT. M.MacherouxP. (2007). 6-S-cysteinylation of bi-covalently attached FAD in berberine bridge enzyme tunes the redox potential for optimal activity. J. Biol. Chem.282, 24437–24443. 10.1074/jbc.M703642200

  • CrossRef
  • Google Scholar

• 255

  WongC. L.RobertsM. B. (1976). The effects of L-histidine and of specific histamine receptor agonists, on the expression of morphine tolerance and physical dependence in mice. Agents Actions6, 569–576. 10.1007/BF01971571

  • CrossRef
  • Google Scholar

• 256

  WróbelM.UbukaT.YaoW. B.AbeT. (1997). Effect of glucose-cysteine adduct on cysteine desulfuration in Guinea pig tissues. Physiol. Chem. Phys. Med. NMR29, 11–14.

  • Google Scholar

• 257

  XuB.WangZ.LiG.LiB.LinH.ZhengR.et al (2006). Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. Basic Clin. Pharmacol. Toxicol.99, 153–161. 10.1111/j.1742-7843.2006.pto_461.x

  • CrossRef
  • Google Scholar

• 258

  XuN.-J.BaoL.FanH.-P.BaoG.-B.PuL.LuY.-J.et al (2003). Morphine withdrawal increases glutamate uptake and surface expression of glutamate transporter GLT1 at hippocampal synapses. J. Neurosci.23, 4775–4784. 10.1523/JNEUROSCI.23-11-04775.2003

  • CrossRef
  • Google Scholar

• 259

  YamaguchiK.HosokawaY. (1987). Cysteine dioxygenase. Methods Enzymol.143, 395–403. 10.1016/0076-6879(87)43069-3

  • CrossRef
  • Google Scholar

• 260

  YangC.ChenY.TangL.WangZ. J. (2011). Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence. J. Pharmacol. Exp. Ther.338, 164–172. 10.1124/jpet.110.175539

  • CrossRef
  • Google Scholar

• 261

  YangL.WangS.SungB.LimG.MaoJ. (2008). Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation. J. Biol. Chem.283, 21703–21713. 10.1074/jbc.M800809200

  • CrossRef
  • Google Scholar

• 262

  YoungA. P.GruberR. B.DiscalaJ. F.MayW. J.PalmerL. A.LewisS. J.et al (2013). Co-activation of μ- and δ-opioid receptors elicits tolerance to morphine-induced ventilatory depression via generation of peroxynitrite. Resp. Physiol. Neurobiol.186, 255–264. 10.1016/j.resp.2013.02.028

  • CrossRef
  • Google Scholar

• 263

  ZamaniN.BuckleyN. A.Hassanian-MoghaddamH. (2020). Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Crit. Care24, 44. 10.1186/s13054-020-2740-y

  • CrossRef
  • Google Scholar

• 264

  ZuberiA.LutzC. (2016). Mouse models for drug Discovery. Can new tools and technology improve translational power?ILAR J.57, 178–185. 10.1093/ilar/ilw021

  • CrossRef
  • Google Scholar